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CHAPTER I 
 
INTRODUCTION 
 
The identification of genes implicated in human disease using genome wide 
association studies 
In recent years, genome wide association (GWA) studies have replaced linkage 
analyses and candidate gene approaches and have been widely used to elucidate the genes 
involved in complex human conditions such as variations in fasting blood glucose and 
type 2 diabetes [1].  Previously, linkage analyses primarily had been used to identify rare 
familial genetic variants with large impacts on human health, such as those causing 
maturity-onset diabetes of the young (MODY), through the comparison of DNA 
segments shared among family members affected with a particular disorder [2].  TCF7L2, 
the gene encoding transcription factor 7-like 2, was identified as a type 2 diabetes-
associated gene using the linkage analysis approach [3].  The candidate gene approach 
focused on the association of candidate genes or genes that would logically be involved 
in a particular disease [1].  Both PPARG and KCNJ11, which encode for peroxisome 
proliferator-activated receptor (PPARγ) and the major subunit of the inward-rectifying 
ATP-sensitive K+ channel (Kir6.2), respectively, were shown to be associated with type 2 
diabetes using this method [4-6].  Both proteins are now targets for anti-diabetes 
medications [1].  While linkage analyses provide an unbiased approach to assessing a 
given disease, the gene must have a relatively large effect on the condition.  In contrast, 
the candidate gene approach can be used to assess more complex diseases and genes with 
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relatively small effects on the given disease.  The use of GWA methodologies, which 
assay the association of single nucleotide polymorphisms (SNP) across the human 
genome with altered risk for a particular disease or condition, provides both an unbiased 
approach and the ability to identify genes with a more modest impact on the risk of 
disease [1]. 
The GWA study approach has currently identified approximately 21 SNPs that 
are associated with glycemic traits (Table 1.1) and 38 SNPs that are associated with Type 
2 diabetes (Table 1.2) [1].  It is important to note, however, that while the GWA study 
approach is useful in the identification of the genetic basis of complex human conditions 
and diseases, the low odds ratios associated with the variants suggest that individually, 
the variants do not cause changes in β-cell function.  Rather, the GWA approach only 
indicates an increased susceptibility to the given condition.  This suggests that other 
factors such as gene X gene or gene X environment interactions may play an important 
role in the manifestation of the condition. 
An important caveat to the GWA study approach is that the polymorphism is 
typically named after the gene in with which it is in closest proximity [1].  It is important 
to note, however, that the variant may not be directly responsible for the observed 
phenotype, but rather may be in linkage disequilibrium (LD) with the causative 
polymorphism [1].  In addition, while the polymorphism may be causative, it may instead 
be modulating the activity of a long-range enhancer and thereby affecting the expression 
of distant genes [1].  It is, therefore, important to perform follow up studies to determine 
whether the gene in question is, in fact, responsible for the observed phenotype.  Thus, 
the goal of the studies described within this thesis is to provide evidence that  
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Table 1.1.  Genes identified in GWA studies that are associated with fasting 
plasma glucose (Adapted from Ref. [7]). 
 
Locus Marker Location of 
SNP 
Allele 
(Effect/Other)a 
Frequency 
of glucose 
raising 
allele 
Effect 
(mmol/l/allele) 
G6PC2 rs560887 
 
rs13431652 
 
rs573225 
Intron 3 
 
Distal 
promoter 
 
Proximal 
promoter 
C/T 
 
A/G 
 
A/G 
0.69 
 
0.68 
 
0.66 
0.071 
 
0.075 
 
0.073 
GCK rs4607517 36 kb 
upstream 
A/G 0.2 0.062 
GCKR rs780094 Intron 16 C/T 0.62 0.029 
 
aEffect represents the allele associated with increased FPG.  Other represents the allele 
associated with reduced FPG. 
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Table 1.2.  Genes identified in GWA studies that are associated with Type 2 diabetes 
(Adapted from Ref. [7]). 
 
Locus Marker Location of 
SNP 
Allele 
(effect/other)a 
Frequency 
of type 2 
diabetes 
susceptibility 
allele 
Odds 
ratio 
SLC30A8 rs13266634 Arg325Trp C/T 0.75 1.12 
HHEX rs1111875 7.7 kb 
downstream 
C/T 0.56 1.13 
TCF7L2 rs7903146 Intron 3 T/C 0.25 1.37 
IGF2BP-2 rs4402960 Intron 2 T/G 0.29 1.17 
PPARγ rs1801282 Pro12Ala C/G 0.92 1.14 
KCNJ12 rs5219 Glu23Lys G/T 0.4 1.15 
FTO rs8050136 Intron 1 A/C 0.45 1.15 
CDKN2A/B rs10811661 125 kb 
upstream 
T/C 0.79 1.20 
CDKAL1 rs7754840 Intron 5 C/G 0.31 1.12 
 
aEffect represents the allele associated with increased FPG.  Other represents the allele 
associated with reduced FPG. 
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polymorphisms within two genes identified in GWA studies, G6PC2 [8] and SLC30A8 
[9], which encode an islet-specific glucose-6-phosphatase, G6PC2, and an islet-specific 
zinc transporter, ZnT-8, are causative for variations in fasting blood glucose and type 2 
diabetes, respectively. 
 
Hepatic glucose-6-phosphatase and glucose homeostasis 
The liver plays a major role in maintaining tight regulation of whole body glucose 
homeostasis.  In the postprandial state, the liver takes up glucose and after conversion to 
glucose-6-phosphate (G6P) either metabolizes it through the glycolytic or pentose 
phosphate pathways or stores it as glycogen.  In the preprandial state when dietary 
glucose is not readily available, the liver is responsible for glucose production from either 
gluconeogenic precursors, such as glycerol, amino acids or lactate, or from glycogen 
breakdown.  The observation that both gluconeogenesis and glycogenolysis result in a 
phosphorylated glucose molecule indicated that there must be an enzyme that could 
remove the phosphate group [10] though, because of its location within the endoplasmic 
reticulum (ER) membrane and its instability, isolation of the enzyme proved difficult [11, 
12].  The cDNA encoding the glucose-6-phosphatase catalytic subunit (G6PC) was 
finally cloned in 1993, however, by Chou and colleagues who took advantage of a mouse 
model with radiation induced chromosomal deletions at the albino locus [13, 14].  This 
mouse strain displayed severe hypoglycemia and lethality shortly after birth as a result of 
reduced gluconeogenic enzyme activity including that of glucose-6-phosphatase [15].  
Chou and colleagues screened a murine liver cDNA library with probes representing the 
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mRNA populations from either wild type or albino deletion mutant mice and isolated the 
cDNA encoding the murine glucose-6-phosphatase catalytic subunit [14, 16]. 
Glucose-6-phosphatase, the enzyme responsible for the terminal step of both 
gluconeogenesis and glycogenolysis, namely hydrolysis of glucose-6-phosphate (G6P) to 
produce glucose, is primarily expressed in the liver and kidney, with low expression also 
present in the pancreas and small intestine [14, 17, 18].  It is currently accepted that 
glucose-6-phosphatase is a multi-component enzyme system that consists of both the 
catalytic subunit as well as transporters for the substrates and products, termed the Arion 
substrate-transport hypothesis (Fig. 1.1) [19, 20].  In this model, the catalytic subunit, 
G6PC, responsible for G6P hydrolysis, has an active site that faces the ER lumen in the 
adult, though this orientation is reversed in the fetus [21].  Thus, the G6Pase system must 
also possess transporter activity to shuttle both substrate and product across the ER 
membrane.  Subsequently, a G6P translocase (G6PT) responsible for delivering the 
substrate to the ER lumen was identified based on its homology to a known G6P 
transporter located on the inner membrane of Escherichia coli, UhpT [22].  Using an 
expressed sequence tag (EST) database, a mouse and human cDNA were identified that 
shared approximately 20% identity with the bacterial transporter.  The G6PT is thought to 
lend specificity to the system as it is almost specific for G6P [20].  In intact cells, 
hydrolysis of mannose-6-phosphate (M6P) occurs at a rate of 5% of that of G6P [23].  
When the membrane is disrupted, however, the rates of hydrolysis of G6P and M6P are 
similar [23].  Furthermore, UhpT is known to act as an antiporter, exchanging one 
molecule of a phosphate ester with one or two molecules of inorganic phosphate, 
depending on the pH [24].  Consistent with this observation, it is now thought that this  
	   7	  
 
 
Figure 1.1.  Model of the glucose-6-phosphatase multicomponent enzyme system. 
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same transporter shuttles inorganic phosphate back into the cytoplasm [25].  The glucose 
transporter in this system has yet to be identified. 
 
Hepatic glucose-6-phosphatase and human disease 
Both decreases and increases in glucose-6-phosphatase activity have been linked 
to human disease states.  Reduced glucose-6-phosphatase activity results in glycogen 
storage disease (GSD), a group of autosomal recessive disorders.  GSD type 1a is caused 
by mutations in G6PC and is characterized by heptomegaly and nephromegaly as a result 
of increased glycogen deposition, hypoglycemia in the fasted state, renal failure and 
growth retardation [26].  Both GSD type 1b and GSD type 1c are caused by mutations in 
G6PT and present similarly to GSD type 1a with patients also having increased 
susceptibility to bacterial infection due to neutrophil dysfunction [27].  Interestingly, 
though the G6P translocase is expressed in leukocytes, the G6PC catalytic subunit is not.  
This suggests an additional role of G6PT and is consistent with the presence of another 
isoform, G6PC3, in this cell type. 
Increased glucose-6-phosphatase activity is characteristic of both type 2 diabetes 
and in some cases of type 1 diabetes.  Typically, a 2-4-fold increase in mRNA levels and 
a 2-3-fold increase in G6Pase activity is observed in patients with diabetes [28-30], 
presumably the result of a relative (type 2) or absolute (type 1) reduction in insulin 
signaling.  Insulin signaling has been shown to regulate G6PC gene transcription through 
an insulin response unit composed of a hepatocyte nuclear factor-1 (HNF-1) binding site 
located between -231 and -199 [31] and two FOXO1 binding sites located between -198 
and -159 [32, 33].  HNF-1 is thought to act as an accessory factor that stabilizes the 
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binding of FOXO1 [34, 35].  Insulin signaling targets FOXO1 resulting in its nuclear 
exclusion [36-43]. Because FOXO1 acts as a transcriptional activator in this gene its 
removal from the nucleus results in a decrease in G6PC transcription.  Thus, an 
inappropriate elevation in G6PC due to altered insulin signaling therefore results in 
inappropriate glucose production, exacerbating the hyperglycemia observed in type 2 
diabetes. 
 
The glucose-6-phosphatase gene family 
 The glucose-6-phosphatase gene family comprises three members: G6PC, G6PC2 
and G6PC3.  The identification of G6PC2 came out of the observation that though 
glucose-6-phosphatase activity was present in the pancreatic β-cell, the kinetics differed 
from that observed in the liver.  Specifically, glucose-6-phosphatase activity in 
insulinoma microsomes is approximately one quarter of the activity observed in liver 
microsomes (33.1±6.4 vs. 132.7±24.9 nmol/min/mg) [44].  In addition, islet glucose-6-
phosphatase displays a KM value, pH optima, and inhibitor profile distinct from the liver, 
suggesting either the presence of an alternative glucose-6-phosphatase isoform in islets or 
a regulatory factor that alters the behavior of the same isoform that is present in liver [44, 
45].  The isolation of a cDNA cloned from mouse insulinoma tissue that encodes a 355-
amino acid protein and shares 50% identity with G6pc favors the former explanation.  
This protein was found to be restricted to the pancreatic islets and was subsequently 
named the islet-specific glucose-6-phosphatase catalytic subunit related protein (IGRP) 
[44].  This protein has now been renamed G6PC2. 
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In addition to G6PC and G6PC2, a third isoform in the glucose-6-phosphatase 
gene family was identified using a BLAST search with human G6PC2 as the query and 
was named the ubiquitously expressed glucose-6-phosphatase catalytic subunit related 
protein (UGRP) due to its expression in a wide variety of tissues, particularly heart, 
skeletal muscle, brain, kidney and pancreas. This protein has now been renamed G6PC3.  
G6PC3 shares 36% homology with G6PC [46]. 
Table 1.3 summarizes the characteristics of the G6PC family [47].  Both G6PC 
and G6PC3 are located on chromosome 17, while G6PC2 is located on chromosome 2.  
All three G6PC isoforms encode proteins that are located in the ER, are a similar length 
and are predicted to share a similar topology and 9 transmembrane domain structure. 
While it has been well established that G6PC is capable of G6P hydrolysis, the 
glucose-6-phosphatase activity of G6PC2 and G6PC3 has been less clear.  Though, based 
on its structure and the conservation of a number of critical residues, G6PC2 would be 
predicted to hydrolyze glucose-6-phosphate, initial data from the Hutton laboratory using 
Cos7 cells transiently transfected with G6pc2 failed to demonstrate G6P hydrolysis [44, 
48, 49], as did experiments performed by the Chou laboratory [50].  Under different 
conditions, however, Petrolonis and colleagues were able to demonstrate that G6pc2 is 
capable of hydrolyzing G6P [45].  Since this report, the Hutton laboratory has re-
evaluated the issue.  By permeabilizing the membrane to G6P with minimal perturbation 
of the intracellular membrane architecture, they were able to demonstrate that G6pc2 is 
capable of G6P hydrolysis (Fig. 1.2) [47].  It is important to note, however, that it does so 
with a lower KM and VMAX than G6pc [45]. 
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Table 1.3.  The glucose-6-phosphatase catalytic subunit gene family. 
 
Gene	   G6Pase	   Islet-­‐Specific	  
G6Pase-­‐Related	  
Protein	  (IGRP)	  
Ubiquitous	  
G6Pase	  Related	  
Protein	  (UGRP)	  
	   G6PC	   G6PC2	   G6PC3	  
Tissue	   Liver	   Islet	  β-­‐cell	   Ubiquitous	  
Size	   357	  aa	   355	  aa	   346	  aa	  
%	  Identity	   100	   50	   36	  
Chromosome	   17q21	   2	   17q21	  
Location	   ER	   ER	   ER	  
#Transmembrane	  
domains	  
9	   9	   9	  
Substrate	   G6P	   G6P	   G6P	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Figure 1.2.  G6PC2 possesses glucose-6-phosphatase activity in permeabilized cells.  
The glucose-6-phosphatase activity of G6PC2 was measured in COS7 cells under several 
membrane permeabilization conditions.  COS7 cells were transfected with either 
pcDNA3.1 (white bars) or pcDNA3.1 containing human G6PC2 (grey bars).  48 hours 
after transfection, cells were harvested, pelleted and resuspended.  Cells were then 
permeabilized with limited disruption of the internal membranes using the indicated 
treatment prior to assaying for glucose-6-phosphatase activity using a radiochemical 
assay.  F/T=freeze thawing; Soni.=sonication; Digi.=0.1% digitonin for 15 min. on ice; 
Ala.=0.02% alamethicin for 15 min. on ice.  Results are means ± S.E.M. 
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Though the Hutton laboratory was also unable to demonstrate G6P hydrolysis by 
G6PC3 when expressed in COS cells using transient transfections at the same levels as 
G6PC [46], other labs have been able to show that G6PC3 can serve as a glucose-6-
phosphatase when expressed at much higher levels using either stable [51] or adenoviral 
[52] transfections.  The reason(s) for this discrepancy remain unclear.  The estimated 
VMax value for G6PC3 is approximately one sixth of G6PC while the KM values are 
similar [52, 53].  Studies in G6pc3 KO mice have confirmed that deletion of G6pc3 
impairs G6P hydrolysis in brain and testis homogenates [53].  In addition, another study 
found that G6pc3 KO mice demonstrate neutropenia and defective neutrophil function 
[54], consistent with observations that mutations in G6PC3 in humans result in severe 
congenital neutropenia syndrome [55]. 
 
Glucose-6-phosphatase activity in the ß-cell 
Though the liver and to a lesser extent, the kidney, are the primary glucose 
producing organs, G6PC expression and glucose-6-phosphatase activity have been 
detected in other organs, including the pancreatic ß-cell [56].  This was a surprising 
observation because the ß-cell was not known to contribute appreciably to 
gluconeogenesis.  Rather, it is well established that the primary function of the ß-cell is to 
secrete insulin in response to glucose and other nutrients.  Thus, it has been hypothesized 
that an islet glucose-6-phosphatase would serve to modulate glucose stimulated insulin 
secretion (GSIS) [57]. 
As glucose levels rise in the blood, glucose enters the ß-cell through the high-KM 
glucose transporter, GLUT2, and is then phosphorylated by glucokinase and further 
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metabolized by the glycolytic pathway and the tricarboxylic acid (TCA) cycle (Fig. 1.3).  
This results in a rise in ATP levels and consequently the ATP:ADP ratio, which causes 
the closure of the ATP-sensitive potassium (KATP) channels.  The decrease in potassium 
influx leads to the depolarization of the ß-cell membrane and the opening of voltage-
gated calcium channels and influx of calcium.  Intracellular calcium concentrations rise, 
activating the exocytotic machinery, which then allows fusion of the insulin vesicles with 
the cellular membrane and subsequent insulin secretion. 
Though this has long been the accepted model of GSIS, more recent studies 
suggest an important role for a KATP channel-independent mechanism of GSIS [58].  
While the regulation of KATP channels appears to be particularly important for the 
triggering signal of GSIS [59, 60], the amplifying pathway of GSIS seems to rely on KATP 
channel independent mechanisms [61].  This concept is supported by the observation that 
mice that lack KATP channel function due to the loss of either of the channel subunits 
retain GSIS and maintain glucose homeostasis [62-65].  Additional studies have indicated 
that pyruvate metabolism, and specifically the byproducts of the pyruvate/isocitrate cycle, 
NADPH and α-ketoglutarate, may play a key role in the KATP-independent mechanism of 
GSIS [66, 67]. 
It is critical that insulin is secreted in proportion to circulating glucose levels in 
order to tightly maintain glycemia.  The ß-cell must, therefore, have a mechanism in 
place for accurately coupling blood glucose concentrations to insulin secretion.  There 
have been two primary proteins that have been considered candidates for the ß-cell 
glucose sensor: GLUT2 [68, 69] and glucokinase [70].  Though both proteins have KM 
values within the physiological range [71, 72] a number of studies in isolated islets,  
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Figure 1.3.  Glucose-6-phosphatase activity and the futile cycle in the pancreatic β-
cell.  The presence of glucose-6-phosphatase activity in the β-cell opposes glucokinase 
activity and results in a futile cycle.  This would be predicted to result in the hydrolysis of 
ATP without regeneration thus lowering insulin secretion. 
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immortalized cell lines and transgenic mice have suggested that glucokinase, rather than 
GLUT2, serves as the glucose sensor and that glucose transport is not limiting [73].  For 
example, transgenic mice overexpressing a yeast isoform of glucokinase exhibit 
increased plasma insulin and reduced plasma glucose concentrations as well as enhanced 
GSIS from isolated islets [74].  Furthermore, transgenic mice in which glucokinase 
expression has been knocked down display an increased threshold for GSIS in pancreas 
perfusions [75].  In contrast, neither overexpression of GLUT1 [73] nor attenuation of 
GLUT2 expression by 90% [76] in transgenic mice affects GSIS.  The prevailing dogma 
has, therefore, been that glucokinase serves as the ß-cell glucose sensor. 
The observation that glucose-6-phosphatase activity exists in the ß-cell, however, 
brings this model into question.  Glucokinase and an islet glucose-6-phosphatase would 
be predicted to form a futile cycle in which ATP is used during the phosphorylation step 
(Fig. 1.3).  This would result in a relative decrease in the ATP:ADP ratio and attenuation 
of GSIS.  Although this system is metabolically inefficient, it would allow multiple 
inputs to be integrated and the set point of GSIS to be more finely tuned than with 
glucokinase alone.  It is, therefore, conceivable that an islet glucose-6-phosphatase could 
serve as a negative component of the ß-cell glucose sensor. 
Consistent with this hypothesis, a number of studies have been able to detect 
glucose cycling in the murine islet at, albeit, low levels.  Khan and colleagues, using 
healthy control islets and either islets isolated from ob/ob mice or streptozotocin-induced 
diabetic rats, estimated glucose dephosphorylation to occur at a rate of approximately 3-
4.5% of glucose phosphorylated in the healthy islets and 40% and 15.7% in the ob/ob and 
diabetic rat islets, respectively [77, 78].  In contrast, studies using islets isolated from 
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healthy rats have suggested that although glucose-6-phosphatase is present, activity levels 
are too low to significantly affect glucose cycling and GSIS [79].  An important caveat to 
this study, however, is that the authors used rat islets that were freshly isolated and 
cultured in low glucose.  It has been well established that glucose stimulates rat G6pc 
gene transcription [80-82] and, thus, in low glucose conditions, G6pc activity would be 
expected to be relatively low.  Whether the level of glucose-6-phosphatase activity and of 
glucose cycling is sufficient to significantly affect GSIS in vivo remains unknown. 
 
Transcriptional regulation of G6PC2 
G6pc2 expression has been detected primarily in pancreatic ß-cells as well as a 
subset of α-cells [83].  Studies in our lab suggested that a short region of the promoter 
from -306 to +3, relative to the transcription start site, was sufficient to drive reporter 
gene expression in β-cell lines [84].  Surprisingly, however, while this region was 
sufficient to confer islet-specific transgene expression in mice beginning at embryonic 
day 12.5, like the endogenous G6pc2 gene, the minimal promoter was unable to confer 
sustained transgene expression in the adult [83].  This observation suggests that the 
mechanisms by which G6pc2 promoter activity is regulated differ in cell lines as 
compared to in vivo and that cell lines may resemble the fetal state.  A number of putative 
enhancer elements have since been identified 5’, within and 3’ of the G6pc2 gene [85], 
and our lab is currently in the process of determining which regions are critical for 
maintaining gene expression in the adult. 
The transcription factors driving activity of the proximal (-306/+3) promoter have 
been thoroughly investigated.  Originally, the goal of this work was to identify novel, 
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islet-enriched transcription factors that are important for islet function and/or 
development.  Because the derivation of insulin-secreting β-cells from stem cells 
represents a potential cure for type 1 diabetes, the identification of novel transcription 
factors with a role in islet growth or differentiation could prove to be important for this 
process.  Using in situ footprinting of this highly conserved proximal promoter region, 
key cis-acting sites were identified [86].  Chromatin immunoprecipitation assays and 
mutational analyses later indicated that Pdx-1, Pax-6, MafA, Foxa2, BETA-2 and USF 
bind this region in insulinoma βTC3 cells and regulate promoter activity [87-89].  
Interestingly, the same group of factors has been shown to bind and regulate the insulin 
promoter [90-92]. 
 
Association of G6PC2 with human disease 
Recent GWA studies have identified a number of SNPs within the human G6PC2 
gene that are associated with variations in fasting plasma glucose (FPG) levels in healthy, 
normoglycemic individuals [8, 93-95].  SNP rs560887 is located within the third intron of 
the G6PC2 gene [8] and our lab has recently demonstrated that it affects splicing 
efficiency (Devin Baerenwald and Richard O’Brien, unpublished data).  Each additional 
A allele, the minor allele, is associated with approximately a 1mg/dl reduction in fasting 
plasma glucose levels [8].  An additional SNP, rs13431652, located in the G6PC2 
promoter, was also shown to associate with a similar variation in FPG due to altered 
binding of the transcription factor NF-Y [96].  Specifically, the rs13431652-A allele is 
associated with increased FPG and increased promoter activity due to stronger NF-Y 
binding [96].  Interestingly, a third SNP, rs573225, was also shown to associate with FPG 
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and it was demonstrated that the region binds Foxa2 in insulinoma cell lines [95, 96].  
The rs573225-A allele, however, is associated with elevated FPG in humans but with 
reduced promoter activity in cell lines [96], an observation inconsistent with expected 
results and the data from SNPs rs560887 and rs13431652.  Our laboratory has interpreted 
this result as revealing the potential limitation of using insulinoma cell lines to follow up 
on human GWA study data. 
Though these variations in FPG seem relatively minor, it is important to note that 
small variations in FPG can have a significant impact on human health.  For example, 
one study demonstrated that, in a European population, an increase in fasting plasma 
glucose from <90 mg/dl to between 99 and 108 mg/dl is associated with a 30% increased 
risk of cardiovascular associated mortality (CAM) [97].  A separate study performed in 
an Asian population indicated that a reduction in fasting plasma glucose from 99 mg/dl to 
90 mg/dl results in a 25% reduction in the risk of CAM [98].  Furthermore, it has been 
well established that increased fasting plasma glucose is a risk factor for type 2 diabetes 
[99]. 
More recent studies, however, have challenged these ideas.  Sarwar and 
colleagues found that within normal FPG concentrations, between 70 and 100 mg/dl, 
FPG does not associate with CAM in a meta-analysis of 102 prospective studies [100].  
Furthermore, it was shown that plasma glucose levels one hour after a glucose tolerance 
test are actually a better predictor of type 2 diabetes than FPG [101].  Finally, although 
SNPs within the G6PC2 gene associate with FPG within the normal range, Heni and 
colleagues demonstrated that in patients with elevated FPG, SNPs within the G6PC2 
gene no longer influence glycemia [102].  While the role of G6PC2 in CAM has not yet 
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been directly investigated, these studies do suggest that G6PC2 may not play a significant 
role in disease but may rather be important for shutting off insulin secretion, as described 
in the next section. 
In addition to G6PC2, a number of other genes have also been shown to be 
associated with variations in FPG, most notably GCK and GCKR that encode glucokinase 
and the glucokinase regulatory protein, respectively [103, 104] (Table 1.1).  Glucokinase, 
a high KM hexokinase, catalyzes the initial step in glycolysis and glycogen synthesis, the 
phosphorylation of glucose to G6P, in the islet as well as the liver, gut and brain [105] 
and thus, G6PC2 is predicted to oppose the actions of glucokinase.  Glucokinase has 
traditionally been considered the primary glucose sensor [106].  Though mutations within 
the GCK gene have been shown to reduce glucokinase activity, leading to MODY2 [107], 
SNP rs4607517 is located 36 kb upstream of the transcription start site and is associated 
with a small but significant change in FPG levels and hemoglobin A1C (HbA1C) [104].  In 
the post-prandial state, glucokinase is present in the active form in the cytosol.  In the 
post-absorptive state, the glucokinase regulatory protein will associate with glucokinase, 
resulting in nuclear localization, thus rendering glucokinase functionally inactive.  A SNP 
within a GCKR intron, rs780094, is associated with a small variation in FPG [104].  
Because all three genes are closely related in function, it is not surprising that all are 
associated with variations in FPG.  This underscores the putative role of G6PC2 as a 
component of the glucose sensor.  These data also suggest that in this instance the SNPs 
identified in GWA studies are affecting the expression of the genes in which they are 
located rather than affecting enhancers that regulate the activity of distant genes.  Finally, 
not only have SNPs within the G6PC2 gene been associated with FPG, but it has also 
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been shown that SNP rs560887 associates with variations in hepatic glucose production 
as well as insulin secretion after oral and intravenous glucose load [108-110]. 
In addition to CAM, G6PC2 has been implicated in the pathophysiology of type 1 
diabetes.  G6PC2 was identified as the target of the 8.3-like T cell clone, a representative 
clone of the T cell population expressing a shared T cell receptor α chain (Vα17-Jα42), 
in the non-obese diabetic mouse (NOD) [111], a widely studied model of human type 1 
diabetes [112].  It was subsequently identified as a target of cell mediated autoimmunity 
in humans [113, 114] as well as in “humanized mice” [113, 115, 116]. 
Initially, proinsulin and G6PC2 were thought to be likely candidates for the 
primary autoantigen as they are both β-cell specific and early targets of T-cell reactivity 
[111].  Subsequent studies, however, have pointed to the idea that proinsulin is the 
primary autoantigen, while the T cell response to G6PC2 lies downstream, suggesting 
that the autoimmune response to proinsulin spreads to other antigens, such as G6PC2 
[117]. Specifically, using mice overexpressing either proinsulin 2 or G6PC2 in their 
antigen-presenting cells (APCs), it was shown that mice overexpressing proinsulin lacked 
G6PC2-reactive T cells and were diabetes free while those overexpressing G6PC2 still 
developed diabetes [117].  Furthermore, deletion of G6pc2 from NOD mice does not 
prevent or delay the development of type 1 diabetes (Ken Oeser, Luc Van Kaer and 
Richard O’Brien, unpublished data) while NOD mice expressing a non-immunogenic 
form of proinsulin do not develop type 1 diabetes [118]. 
Though these studies point to a primary role for insulin and the existence of 
epitope spreading, it is not known whether this phenomenon is actually a required step in 
the development of diabetes. The data only suggest that autoimmunity toward G6PC2 is 
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not required for the development of type 1 diabetes but, given the existence of multiple 
autoantigens, the phenomenon of epitope spreading may still be required for disease 
progression. 
 
G6pc2 function in vivo 
The presence of glucose-6-phosphatase activity in the islet β-cell is a surprising 
observation given that the islet does not contribute significantly to whole body 
gluconeogenesis.  Rather it seems more likely that an islet glucose-6-phosphatase could 
oppose glucokinase and modulate GSIS.  In order to gain insight into the function of 
G6pc2, our lab obtained G6pc2 knockout (KO) mice and examined the phenotype on a 
mixed C57BL/6J x 129SvEv genetic background.  At 16 weeks of age, no difference in 
fasting plasma insulin or glucagon levels was observed but there was a small but 
significant reduction in fasting blood glucose (FBG) levels in both male (-14%) and 
female (-11%) KO mice following a 6 hour fast [119]. 
 
Hypothesis on the role of G6pc2 in vivo 
Based on the evidence outlined here, we hypothesize that G6PC2 acts as a 
glucose-6-phosphatase and serves as an inhibitory component of the beta cell glucose 
sensor, which determines glycolytic flux and modulates the S0.5 of GSIS.  Thus, we 
predict that deletion of G6pc2 in mice will result in a leftward shift in GSIS with no 
change in VMAX (Fig. 1.4).  To address this hypothesis our laboratory did perform 
hyperglycemic clamps on the mixed background mice to determine whether insulin 
secretion was elevated in the KO mice but we failed to detect a difference [119].  One  
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Figure 1.4.  Hypothesized effect of G6pc2 deletion in mice on GSIS dose-response 
curve.  G6pc2 is hypothesized to serve as a negative component of the β-cell glucose 
sensor thus determining glycolytic flux.  Deletion of G6pc2 in mice is expected to result 
in a leftward shift in the dose-response curve of GSIS. 
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limitation to this approach is the large variation observed between mice on the mixed 
genetic background, which may explain why we were unable to detect a difference.  
Thus, more sophisticated analyses of insulin secretion have been performed on G6pc2 
KO mice on a pure C57BL/6J background and are described in Chapter III. 
In addition to deletion of G6pc2, one study has also analyzed the effect of 
overexpression of G6PC2 using a transgenic mouse model expressing human G6PC2 
under the control of the rat insulin promoter (RIP) in NOD mice.  Overexpression of 
G6PC2 results in increased cell death due to ER stress and consequently diabetes [120].  
It was hypothesized that this is likely due to the generation of unfolded proteins in the ER 
[120]. 
 
Zinc homeostasis 
Zinc plays a critical role in many functions in vivo and thus, zinc levels are tightly 
regulated [121].  Whole body zinc levels in adults are usually between 2 and 4 g while 
plasma levels are typically 12-16 µM [122].  The highest concentrations of zinc are found 
in the prostate, eye, brain, muscle, bones, kidney and liver [123].  Zinc acts as a cofactor 
and is critical for proper functioning of over 300 enzymes [124, 125].  In addition, it 
plays an important role in many different biological functions, including RNA and DNA 
metabolism, signal transduction, gene expression, metabolic enzyme activity, and 
protection against apoptosis and oxidative stress [121].  For example, zinc is used as a 
catalytic agent for both carbonic anhydrase and carboxypeptidase, enzymes responsible 
for carbon dioxide regulation and protein digestion, respectively [126].  Within the 
pancreas, some of the highest levels of zinc are present in the islet where zinc 
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concentrations are 10-12 mg/100 g tissue [127], approximately 4-fold higher than in the 
surrounding acinar tissue [128].  Zinc localizes to the insulin secretory granules [128], 
where it is thought to be important in the pancreatic ß-cell for proper insulin processing 
and secretion [129].  Alterations in zinc homeostasis are associated with a number of 
diseases including diabetes [122].  Thus, whole body zinc homeostasis is tightly 
regulated.  This regulation is mediated by two classes of molecules, specifically 
metallothioneins and zinc transporters. 
 
Metallothioneins 
Metallothioneins are members of a superfamily of intracellular metal binding 
proteins and are capable of binding a number of metals including copper, cadmium and 
zinc [130].  Conserved cysteine residues within the proteins bind zinc and modulate zinc 
trafficking and storage [130].  Furthermore, metallothioneins are responsible for carrying 
zinc ions within a cell from one organelle to another, serving as a critical component of 
zinc signaling systems, and are thought to protect both α- and β-cells from oxidative 
stress [131, 132]. 
In mammals there are four genes, MT1-4, that encode metallothionein isoforms.  
In mice, the four genes are located within 50kB of one another on chromosome 8 [133].  
In humans, a cluster of genes located on chromosome 16 encode the multiple isoforms of 
MT1, designated by the letters a, b, e, f, g, h and x, as well as MT2 while single genes on 
the same chromosome encode MT3 and MT4 [134-136]. 
Both MT1 and MT2 are widely expressed throughout the body [137] while MT3 is 
primarily expressed in the brain, as well as liver, kidney, intestine and pancreas [138-
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140], and MT4 is detected only in squamous epithelia and maternal deciduum [141, 142].  
High levels of metallothioneins are found in rapidly proliferating cells where they are not 
only found in the cytosol but also within the nucleus [143, 144].  Here, it is thought that 
metallothioneins may serve to either protect DNA from oxidative damage or to provide 
critical cell division enzymes and transcription factors with zinc [144-146].  In addition, 
the highest levels of metallothioneins are present in the liver, kidney, intestine, where 
they regulate both zinc absorption and excretion, and pancreas [134, 147-149]. 
The importance of metallothioneins in the pancreas is underscored by both rodent 
studies as well as human genetic data.  Islets isolated from metallothionein knockout 
mice display reduced GSIS [150], consistent with the important role of zinc in insulin 
secretion.  In addition, streptozotocin-treated mice and rats display increased levels of 
zinc in both the liver and kidney that may be explained by the observed increase in 
metallothionein levels in these organs [131].  Furthermore, transgenic overexpression of 
metallothionein in streptozotocin-treated β-cells in vitro and in vivo results in a reduction 
in streptozotocin-induced β-cell destruction, a delay in the onset of diabetes and a 
reduction in glycemia [151].  In addition, pretreatment of streptozotocin-treated rats with 
zinc supplementation both increases plasma and pancreatic metallothionein levels and 
reduces glycemia [152].  In humans, polymorphisms in both MT1A, rs11640851, and 
MT2A, rs1610216, have been found to be associated with type 2 diabetes, blood glucose 
and HbA1C in a small Chinese cohort of Han descent [153].  Furthermore, polymorphisms 
in these same isoforms, rs11076161 and rs10636 in MT1A and MT2A, respectively, have 
been associated with diabetic neuropathy [153].  Finally, a polymorphism within the 
MT1B gene has been shown to be associated with obesity in humans [153].  These 
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observations are also consistent with data derived from the MT1/2 knockout mouse.  
These mice display increased food intake, increased body weight and increased plasma 
leptin levels [154, 155].  
 
Zinc transporters 
In addition to the important role of metallothioneins in zinc homeostasis, two 
families of zinc transporters facilitate the movement of zinc into or out of cells.  The 
SLC39 (ZIP) family is responsible for cellular uptake of zinc and/or other metal ion 
substrates from either the extracellular matrix or release from intracellular vesicles into 
the cytoplasm while the SLC30 (ZnT) family controls cellular efflux of zinc into the 
extracellular space or into intracellular vesicles [155].  Table 1.4 summarizes the 
characteristics of the ZIP (Zrt, Irt-like protein) family.  Most members are predicted to 
share a similar structure and topology, namely an eight transmembrane domain structure 
with the N- and C-termini predicted to reside on the extracellular membrane [155].  In 
addition, a long loop region is present between domains III and IV that is highly 
conserved and contains a histidine-rich loop that had been predicted to serve as a metal 
binding region [155].  Mutational analysis using the yeast Zrt1 transporter, however, 
suggests that this region may instead alter subcellular localization [156].  Unlike the 
metallothionein or ZnT families, there is no known association of any of the Zip family 
members with type 2 diabetes.  This is surprising given the postulated importance of zinc 
in islet function but it may indicate redundancy of function in this family.  In contrast, a 
number of ZIP family members have been associated with breast cancer [157-160] and 
acrodermatitis enteropathica [161-163]. 
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Table 1.4.  Characteristics of the ZIP family of zinc transporters (Adapted from Ref. 
[155]). 
 	   Dietary	  Zinc	  
Response	  
Tissue/Cell	  
Expression	  
Subcellular	  
Localization	  
Knockout	  
Phenotype	  
Association	  
with	  Human	  
Disease	  
ZIP1	   	   Ubiquitous	   In	  humans,	  membrane	  and	  ER	  (cell	  type	  dependent)	  	  In	  mice,	  intracellular	  organelles	  (+Zn2+);	  cell	  membrane	  (-­‐Zn2+)	  
No	  phenotype	  if	  zinc	  adequate;	  adverse	  developmental	  effects	  when	  zinc	  deficient	  
	  
ZIP2	   	   Prostate,	  uterus,	  cervical	  epithelium,	  optic	  nerve,	  monocytes	  
	   	   	  
ZIP3	   	   Testes	   Intracellular	  organelles	  (+Zn2+);	  cell	  membrane	  (-­‐Zn2+)	  
	   	  
ZIP4	   	   Small	  intestine,	  stomach,	  colon,	  kidney	  
	   	   	  
ZIP5	   mRNA:	  unresponsive;	  Translation:	  abundance	  stimulated	  by	  Zn2+	  supplementation	  
Liver,	  kidney,	  pancreas,	  small	  intestine,	  colon	  
Basolateral	  surface	  (+Zn2+);	  internalized	  (-­‐Zn2+)	  
	   Acrodermatitis	  enteropathica	  
ZIP6	   	   Steroid-­‐hormone	  sensitive	  tissues:	  placenta,	  mammary	  gland,	  prostate	  
Plasma	  membrane	  	   	   May	  play	  a	  role	  in	  breast	  cancer	  progression	  
ZIP7	   Protein	  abundance	  repressed	  by	  Zn2+	  supplementation	  
Ubiquitous	   Golgi	  apparatus	   	   May	  play	  a	  role	  in	  breast	  cancer	  progression	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ZIP8	   	   Lung,	  kidney,	  testis,	  liver,	  brain,	  small	  intestine,	  mature	  RBCs	  
Plasma	  membrane	  (-­‐Zn2+);	  internalized	  (+Zn2+)	  (Exception:	  RBCs	  always	  membrane)	  
No	  knockout;	  Resistance	  to	  Cd-­‐induced	  testicular	  toxicity	  observed	  in	  certain	  inbred	  mouse	  strains	  attributed	  to	  Zip8	  variant	  
	  
ZIP10	   Increased	  transcription	  during	  Zn2+	  deficiency	  
	   	   	   May	  play	  a	  role	  in	  metastatic	  breast	  cancer	  progression	  
ZIP12	   	   	   	   	   Schizophrenia	  
ZIP13	   	   	   Golgi	  apparatus	   Reduced	  osteogenesis,	  abnormal	  cartilage	  development,	  reduced	  dentin	  and	  alveolar	  bone,	  abnormal	  craniofacial	  features,	  decreased	  corneal	  stromal	  collagen	  
Spondylocheiro	  dysplastic	  form	  of	  Ehlers-­‐Danlos	  syndrome	  (SCD-­‐EDS)	  
ZIP14	   	   Liver,	  intestine	   Plasma	  membrane	   	   	  *Zip	  9	  and	  Zip11	  have	  not	  been	  characterized.	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The ZnT family of transporters opposes the action of the ZIP family by 
transporting zinc out of the intracellular space.  The 10 members of the ZnT family share 
a similar six transmembrane domain structure with both the N and C terminals located in 
the cytoplasm [155].  Between domains IV and V most members share a histidine-rich 
loop that is thought to bind zinc [155].  ZnT-6 and ZnT-10, however, have a serine-rich 
and a basic amino acid-rich loop, respectively, in its place [155].  Table 1.5 summarizes 
the characteristics of the ZnT family. 
 
Role of zinc in the islet 
Zinc levels in the pancreas are among the most abundant in the body with the 
highest concentrations localized to the pancreatic islets [128].  Free zinc levels are most 
concentrated in the insulin granules, with concentrations of approximately 20 mM [164], 
where zinc has been hypothesized to play a critical role in insulin processing, storage and 
secretion [127].  In the presence of zinc, proinsulin monomers form soluble hexamers 
containing at least two zinc ions coordinated to histidine residues at position B10 [127].  
This solubility favors both transport into the Golgi apparatus, where it is thought that the 
zinc ions help to protect proinsulin from disulfide bond reduction, as well as the 
formation of evaginations that bud off into the insulin secretory vesicles [127, 165].  
Proinsulin is cleaved to form insulin, which is insoluble in the presence of zinc, and the 
newly formed insulin hexamers form a crystalline structure within the vesicles [166].  
The zinc containing crystalline structure is thought to help prevent further proteolysis of 
the protein [129].  Finally, when the insulin secretory granules fuse with the membrane 
and release insulin into the bloodstream, both the increase in pH from 5.5 to 7.4, which  
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Table 1.5.  Characteristics of the ZnT family of zinc transporters (Adapted from Ref. 
[155]). 	   Dietary	  Zinc	  
Response	  
Tissue/Cell	   Subcellular	  
Localization	  
Knockout	  
Phenotype	  
Association	  
with	  Human	  
Disease	  
ZnT1	   Zn2+	  increases	  mRNA	  abundance	  
Ubiquitous,	  specifically	  in	  tissues	  involved	  in	  zinc	  acquisition,	  recycling,	  transfer	  (Ex:	  small	  intestine,	  kidney,	  villous	  yolk	  sac)	  
Plasma	  membrane	   Early	  embryonic	  lethality	   	  
ZnT2	   Zn2+	  upregulates	   Small	  intestine,	  kidney,	  placenta,	  pancreas,	  testis,	  seminal	  vesicles,	  mammary	  gland	  
Vesicles	   	   His59Arg	  mutation	  in	  the	  mother	  results	  in	  neonatal	  zinc	  deficiency	  
ZnT3	   	   Hippocampus	  and	  cortex	  of	  brain	   	   Reduced	  zinc	  content	  in	  synaptic	  vesicles	  in	  brain	  
	  
ZnT4	   Increased	  Zn2+	  induces	  trafficking	  from	  trans-­‐golgi	  network	  to	  cytoplasmic	  vesicular	  compartment	  
Mammary	  gland,	  brain	  intestinal	  epithelial	  cells	  
Vesicles,	  Golgi	  apparatus	   Zinc	  deficient	  milk	  due	  to	  a	  C934T	  mutation;	  lethal	  
	  
ZnT5	   	   Ubiquitous,	  high	  expression	  in	  β-­‐cells	  
Trans-­‐Golgi	  network	   	   	  
ZnT6	   	   Brain,	  lung	   Trans-­‐Golgi	  network	   	   	  
ZnT7	   	   Lung,	  small	  intestine	   Golgi	  apparatus	   Zinc	  deficiency;	  not	  responsive	  to	  supplementation;	  poor	  growth,	  reduced	  body	  fat	  composition	  
	  
ZnT8	   	   Pancreatic	  α-­‐	  and	  β-­‐cell	   Insulin	  secretory	  vesicles	   See	  chapters	  IV	  and	  V	   Type	  1	  and	  2	  diabetes	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ZnT9	   	   Embryonic	  lung	   	   	   	  
ZnT10	   	   Fetal	  liver	  and	  fetal	  brain	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results in the deprotonation of critical carboxylic acid resides, as well as the dilution of 
the zinc molecules results in the repulsion of the individual insulin molecules and the 
disintegration of the crystalline hexamer [129].  Thus, the presence of zinc within the 
insulin granules has long been thought to be critical for proper β-cell function. 
The observation that some species, such as the guinea pig and the Atlantic 
hagfish, do not have a histidine residue at position B10 challenges this concept, however 
[167].  These species have much lower islet zinc levels, between 2 and 3 mg/100 g tissue, 
and consequently do not form insulin hexamers, suggesting that proper insulin secretion 
may be possible in the absence of the crystalline structure [168, 169]. 
Despite this, a number of studies in both mice and humans have supported the 
notion that the presence of zinc is, in fact, critical for β-cell function.  First, zinc 
deficiency in rodents has been shown to result in reduced GSIS and islet insulin content 
[170] and well as impaired β-cell granulation [171].  In addition, in two different rodent 
models of type 2 diabetes, the db/db and the ob/ob mouse, zinc levels were reported to be 
markedly lower than in controls [172, 173].  Interestingly, zinc supplementation in both 
models attenuated the characteristic hyperglycemia and hyperinsulinemia [172, 173] 
while a zinc deficient diet in the db/db mice exacerbated the phenotype [173].  Similarly, 
it was observed that cadavers of individuals with type 2 diabetes had approximately a 
50% reduction in pancreatic zinc content as compared to cadavers of individuals without 
type 2 diabetes [174].  Furthermore, patients with type 2 diabetes have reduced plasma 
zinc levels, increased zincuria and cellular depletion of zinc levels [175].  This 
presumably occurs as a result of hypersecretion of insulin.  As the zinc is secreted along 
with the insulin hexamers, the increase in insulin secretion results in cellular depletion of 
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zinc and an increase in zincuria to dispose of circulating zinc.  Although the β-cell can 
compensate, at least initially, for the increased insulin demand, it is unable to make more 
zinc.  Thus, over time, there is a slow loss of whole body zinc.  Along these same lines, 
zinc supplementation in humans reportedly improves glucose handling [176]. 
Not only is zinc thought to be important for proper β-cell function, but studies 
have also suggested a possible role for zinc in α-cell function.  In vitro and in situ studies 
have suggested that the zinc that is secreted with the insulin hexamers can act as a 
paracrine signal by binding the SUR1 subunit of the KATP channels on the α-cell surface 
[177].  This results in activation of the channels and a subsequent reduction in glucagon 
secretion [177].  Though a separate study was unable to replicate the mechanism of these 
findings, they were able to confirm that zinc inhibits glucagon secretion [132].  In 
addition, it has been speculated that zinc molecules may also affect insulin secretion 
through a similar mechanism and may thereby serve as a negative feedback signal [178]. 
In addition to its positive effects on glucose metabolism, it has also been well-
established that zinc serves an important role in the prevention of apoptosis.  Zinc serves 
as a cofactor to a number of antioxidant enzymes including catalase, peroxidase and 
Cu/Zn superoxide dismutase, thus providing protection against free radicals and oxidative 
stress [179, 180].  Furthermore, in chemically-induced rodent models of type 1 diabetes, 
such as alloxan- or streptozotocin-induced diabetes, zinc supplementation was able to 
prevent type 1 diabetes and improve hyperglycemia [181, 182].  It is important to note, 
however, that though zinc deficiency is clearly harmful, increased levels, such as those 
seen during insulin resistance and the early stages of type 2 diabetes may also be toxic to 
the cells.  In fact, studies performed in both the MIN6 insulinoma cell line as well as in 
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human islets suggested that high levels of zinc are capable of inducing apoptosis as well 
[183, 184]. 
 
Role of ZnT-8 in the islet 
SLC30A8 is highly expressed in the pancreatic β-cell and within these cells is 
thought to colocalize to the insulin secretory vesicles [128].  Though it is not the only 
SLC30 family member that is present in the β-cell, it is the most abundantly expressed 
isoform, at least at the RNA level, and it is the only isoform that is primarily expressed in 
this tissue [185].  Thus, it has been proposed that ZnT-8 is the principal transporter 
responsible for supplying zinc to the insulin secretory granules [186].  It is, therefore, 
reasonable to expect that, in the absence of compensation from other ZnT family 
members, loss of ZnT-8 would result in impaired β-cell function. 
In vitro studies have supported this hypothesis.  Knockdown of Slc30a8 mRNA in 
INS1E cells results in both a reduction in exogenous zinc uptake as well as impaired 
insulin secretion [187].  In contrast, overexpression of ZnT-8 in the same cell line results 
in increased intracellular zinc levels and enhanced GSIS at high glucose [188].  These 
results are consistent with the hypothesis that ZnT-8 serves as the primary zinc 
transporter on the insulin granules and is critical for proper insulin secretion.  The role of 
ZnT-8 in vivo, however, had not been investigated.  Chapter IV describes an initial 
characterization of the Slc30a8 KO mice on the mixed C57BL/6J x 129SvEv genetic 
background.  Chapter V describes a further characterization of the Slc30a8 KO allele on 
the C57BL/6J genetic background as well as addressing some of the discrepancies from 
the different published studies on Slc30a8 KO mice. 
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Association of ZnT-8 with human disease 
A SNP within the human SLC30A8 gene, rs13266634, was initially implicated in 
altered risk for the development of type 2 diabetes in a French cohort [9].  Since the 
original study, these findings have been replicated in a number of populations [103, 189, 
190] and the SNP has also been found to be associated with not only type 2 diabetes, but 
also gestational diabetes [191], proinsulin to insulin conversion [192] and first phase 
insulin secretion [192].  Surprisingly, however, rs13266634 was not associated with type 
2 diabetes in an African-American population [193].  It is important to note, however, 
that the odds ratio for rs13266634 is 1.12 (Table 1.2), suggesting that while SLC30A8 
may contribute to type 2 diabetes susceptibility, this variant alone does not cause 
significant β-cell dysfunction. 
This nonsynonymous polymorphism results in an arginine to tryptophan 
conversion at position 325 within the ZnT-8 protein [9] and in vitro studies have 
suggested that this SNP, which forms part of the dimer interface, mediates zinc uptake 
and accumulation into granules [194].  Studies performed by Nicolson et al have 
demonstrated that cells transfected with a ZnT-8 expression vector containing the 
tryptophan mutation have a reduction in zinc uptake and, consequently, decreased 
granular zinc levels as compared to cells transfected with expression vectors containing 
arginine at position 325 [194].  Interestingly, the same polymorphism identified in the 
GWA studies has also been shown to affect autoantibody epitope specificity in type 1 
diabetes [195].  ZnT-8 was originally identified as an autoantigen in diabetic human 
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subjects [196]. It has yet to be determined whether ZnT-8 is actually recognized by 
human T cells and studies are currently underway to investigate this question. 
 
Hypothesis on the role of ZnT-8 function in vivo 
We hypothesize that ZnT-8 serves as the primary zinc transporter within the islet 
that provides sufficient zinc concentrations to allow for the proper maturation, storage 
and secretion of insulin.  Thus, we predict that deletion of Slc30a8 will result in a 
reduction in islet zinc content and subsequently, impaired insulin secretion.  In order to 
test this hypothesis, we will investigate the phenotype of Slc30a8 KO mice on both a 
mixed C57BL/6J x 129SvEv as well as the pure C57BL/6J genetic background. 
 
Rationale for the use of both mixed genetic background and pure C57BL/6J genetic 
background mice 
 The studies described within this thesis have been performed on both mixed 
C57BL/6J x 129SvEv and pure C57BL/6J genetic backgrounds.  Although the analysis of 
the G6pc2 KO mice described here was performed only on the pure C57BL/6J genetic 
background, the analysis of the mice on the mixed genetic background has been 
described previously [119].  Because the mice are generated on the mixed genetic 
background, initial studies are performed under these conditions.  The mixed genetic 
background is a better representation of a human population than an inbred strain is.  
However, there is also more mouse-to-mouse variability.  Thus, more sophisticated 
analyses were performed on the C57BL/6J genetic background. 
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In contrast to the 129 strain which tends to be more glucose tolerant and insulin 
sensitive than most other strains, C57BL/6 mice are commonly used in the type 2 
diabetes field due to their susceptibility to the development of insulin resistance and type 
2 diabetes [197].  The C57BL/6 mouse bears both diabetes-promoting and diabetes-
protective alleles, resulting in a strain with intermediate diabetes susceptibility [197].  
Thus, C57BL/6 mice are not diabetic themselves but may become so in the context of 
diabetes-promoting conditions [197].  For example, islets isolated from high-fat, high-
simple carbohydrate fed C57BL/6 mice displayed impaired insulin secretion as compared 
to the A/J strain [198, 199].  Altered susceptibility to type 2 diabetes in this strain has 
been mapped to the gene encoding nicotinamide nucleotide transhydrogenase (Nnt), an 
inner mitochondrial membrane enzyme that catalyzes hydride exchange between 
nicotinamide-adenine dinucleotide (NAD+) and NAD phosphate (NADP+) [197].  The 
mutant Nnt allele results in the increased production of reactive oxygen species and thus 
may impair mitochondrial ATP production [200].  Because of the susceptibility to 
impaired β-cell function, the use of the C57BL/6 strain may be particularly useful in our 
studies investigating the effect of deletion of islet-specific genes. 
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CHAPTER II 
 
MATERIALS AND METHODS 
 
Generation of the Slc30a8- and G6pc2-targeting vectors 
The G6pc2 mutant mice were generated and analyzed in collaboration with 
Lexicon Pharmaceuticals and the G6pc2-targetting vector was generated as previously 
described [119]. 
The Slc30a8 mutant mice were generated and analyzed in collaboration with 
Lexicon Pharmaceuticals.  An Slc30a8-targeting vector was derived using the Lambda 
KOS system [201].  The Lambda KOS phage library, arrayed into 96 superpools, was 
screened by PCR using exon 3-specific primers (UTT047-1, 5’-
GTGAGGATAGCCAGACTCC-3’ and UTT047-2, 5’-
CAGCTAGTAATTCAGCACAAC-3’).  The PCR-positive phage superpools were plated 
and screened by filter hybridization using the 516 bp amplicon derived from primers 
UTT047-1 and UTT047-2 as a probe. A pKOS genomic clone, pKOS-36, was isolated 
from the library screen and the presence of the Slc30a8 gene was confirmed by sequence 
and restriction analysis.  Gene-specific arms (5’-
GATATTGTGCATCTCACAGGTGGACACGTTG-3’ and 5’-
CTATATCATTATGCATTCACTATTGCGCAATCAG-3’) were appended by PCR to a 
yeast selection cassette containing the URA3 marker.  The yeast selection cassette and 
pKOS-36 were co-transformed into yeast, and clones that had undergone homologous 
recombination were isolated.  DNA sequencing confirmed that recombination had 
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replaced a 145 bp region, from base pair 13 of exon 3 extending to the first 10 bp of the 
third intron, with the yeast selection cassette.  To complete the Slc30a8-targeting vector, 
the yeast cassette was subsequently replaced with a selection cassette incorporating an 
IRES (internal ribosome entry site), the LacZ gene, the herpes simplex virus TK 
(thymidine kinase) promoter and a Neo (neomycin) selectable marker (Fig.1A of the 
main paper).  The expression of LacZ mRNA is driven by the ZnT-8 promoter with 
translation dependent on the IRES, whereas expression of Neo mRNA is driven by the 
TK promoter. 
 
Generation of G6pc2 and Slc30a8 KO mice 
The G6pc2 KO mice were generated as previously described [119].  For 
generation of the Slc30a8 KO mice, the NotI-linearized targeting vector was 
electroporated into 129SvEvBrd (Lex-2) ES cells.  G418/FIAU-resistant ES cell clones 
were isolated, and correctly targeted clones were identified and confirmed by Southern 
blot analysis using a 354 bp 5’ external probe (9/10), generated by PCR using wild-type 
Lex-2 ES cell genomic DNA as the template with primers (UTT047-9, 5’-
GCTGCAGACTCTTCTCATATGTAG-3’ and UTT047-10, 5’-
CATCTGTAGGCATATAAGTGCATGC-3’), and a 314 bp 3’ internal probe (11/12), 
amplified by PCR using primers (UTT047-11, 5’-
CACAGTCCTCTAAACCCACAGAGTG-3’ and UTT047-12, 5’-
GATGACTACACAAAGGTGAAGAGTG-3’).  Southern blot analysis using probe 9/10 
detected an 8.0 kbp wild-type band and 11.1 kbp mutant band in PstI-digested genomic 
DNA, whereas probe 11/12 detected a 7.6 kbp wild-type band and 12.8 kbp mutant band 
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in NheI-digested genomic DNA.  Correctly targeted clones were also confirmed by PCR 
using the primers indicated below. The primers represented sequences in: exon 3, primer 
1, 5’-GTGAGGATAGCCAGACTCC-3’; intron 2, primer 2, 5’-
CAGCTAGTAATTCAGCACAAC-3’; intron 3, primer 4, 5’-
CCCACAATAACTGCATTGACC-3’; and the Neo gene, Neo3a primer, 5’-
GCAGCGCATCGCCTTCTATC-3’. Cells from the correctly targeted ES cell clone, 
designated 2H8 (Fig. 4.1), were microinjected into C57BL/6 (albino) blastocysts 
resulting in the generation of chimeric mice. 
The C57BL/6J G6pc2 and Slc30a8 KO congenic strains were developed utilizing 
a speed congenic (marker-assisted) breeding strategy [202, 203] as follows.  A male 
G6pc2 or Slc30a8 heterozygous mouse on the mixed 129/SvEvBrd X C57BL/6 
background was bred with three female C57BL/6J mice and the male offspring carrying 
the mutated G6pc2 or Slc30a8 allele and with the highest content of C57BL/6J genome, 
based on the analysis of microsatellite DNA, was selected for the next round of breeding 
with female C57BL/6J mice.  Additional rounds of backcrossing were performed in the 
same manner.  Using this approach backcrossing was complete after 6 generations, with 
the exception of the Y chromosome.  To fix the Y chromosome an additional round of 
breeding was performed in which the male mouse with 100% C57BL/6J genome, based 
on the marker analysis, was bred with female C57BL/6J mice.  Female offspring from 
this breeding were mated with male C57BL/6J mice such that all subsequent offspring 
carried the C57BL/6J Y chromosome. 
Details of the speed congenic breeding strategy are as follows.  A panel of 61 
microsatellite markers, equally spaced throughout the genome (~30 cM intervals), were 
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used to differentiate the genetic background of the originating/donor (129/SvEv) and 
target/recipient (C57BL/6) mouse strains.  Informative markers that distinguish between 
these strains were selected with the aid of a 'panel generator' from 
http://www.cidr.jhmi.edu/mouse/mmset.html.  First, genomic DNA was isolated by 
standard proteinase K digestion protocols.  Genomic DNA was then mixed with True 
Allele PCR Premix (Applied Biosystems, Foster City, CA) and dispensed into a panel of 
Mouse Mapping Primers (Applied Biosystems).  The setup for the multiplexing reaction 
and amplification parameters were followed as per manufacturer specifications.  
Following PCR 4 ml of multiplexed product, 0.6 ml of GS500-ROX size standard 
(Applied Biosystems) and 6 ml of Hi-Di formamide (Applied Biosystems) were mixed, 
denatured at 94°C for 3 min and loaded onto an ABI 3100 Avant Genetic Analyzer.  
Chromatogram data was analyzed using GeneMapper 3.5 software (Applied Biosystems). 
Once mice possessed only C57BL/6J markers, heterozygous mice were bred to 
generate WT, heterozygous and KO mice. 
 
PCR genotyping of G6pc2 and Slc30a8 KO mice 
Mouse-tail DNA was genotyped using PCR in conjunction with primers that 
distinguished between the WT and targeted alleles.  Details of G6pc2 genotyping can be 
found in ref. [119].  Slc30a8 primers WT5’ (5’-TGCGGCTCATCTCTTAATTG-3’) and 
WT3’ (5’-CCTCGATGACAACCACAAAG-3’) were used to amplify a 70 bp product 
from the WT allele whereas primers KO5’ (5’-TTTCCATATGGGGATTGGTG-3’) and 
KO3’ (5’-CTGGAATTCCGCCGATACT-3’) were used to amplify a 61 bp product from 
the targeted allele.  Tail DNA was isolated and purified by standard procedures [204].  
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The WT and targeted allele fragments were amplified using 2.8 ng of genomic DNA and 
iQ SYBR Green Supermix (Bio-Rad) under the following reaction conditions: 94◦C for 
30 s; 60◦C for 30 s; and 72◦C for 30 s (for 40 cycles).  Standard-curve analyses were 
performed for each set of samples to determine the efficiencies of the PCR reactions, 
which were all greater than 95%. 
 
Animal care 
The animal housing and surgical facilities used for the mice in these studies meet 
the American Association for the Accreditation of Laboratory Animal Care standards.  
The Vanderbilt University Medical Center Animal Care and Use Committee approved all 
protocols used.  Mice were maintained on a standard rodent chow diet (LabDiet 5001; 
23% protein and 4.5% fat; PMI Nutrition International) with food and water provided ad 
libitum.  Where specified, mice were placed on a high fat (60% fat calories; Mouse diet 
F3282; BioServ) diet at 8 weeks of age and maintained on the diet for 12 weeks. 
 
Phenotypic analysis of G6pc2 and Slc30a8 KO mice 
Phenotypic analysis was performed on 6 h fasted mice at ~16 weeks of age.  Mice 
were weighed after 5 h fasting and then allowed to recover for one hour prior to being 
anesthetized using isoflurane and bled from the retro-orbital venous plexus.  Whole-blood 
glucose concentrations were determined using an Accu-Check Advantage monitor 
(Roche).  EDTA (5 μl; 0.5 M) was then added to blood samples before centrifugation 
(16000 g for 10 min at 4◦C) to isolate plasma.  Trasylol (aprotinin; 5 μl; Bayer Health 
Care) was added to the plasma to prevent proteolysis of glucagon.  Cholesterol was 
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assayed using the cholesterol reagent kit (Raichem), whereas triacylglycerol and glycerol 
were assayed using a serum triacylglycerol determination kit (Sigma).  Insulin and 
glucagon levels were quantified using radioimmunoassay (Millipore) by the Vanderbilt 
Diabetes Research and Training Center Hormone Assay Core.  Proinsulin was measured 
using the Rat/Mouse Proinsulin ELISA kit (Mercodia) according to manufacturer’s 
instructions. 
 
Intraperitoneal and oral glucose tolerance tests 
Intraperitoneal glucose tolerance tests (IPGTTs) and oral glucose tolerance tests 
(OGTTs) on fasted conscious mice were performed as previously described [205] with 
modifications.  Duration of fast and age of mice are indicated in the respective chapters.  
Briefly, mice were fasted, weighed and then allowed to recover for 1 hour prior to 
injection or oral gavage with either 0.75 or 2.0 mg/g body weight glucose in sterile PBS, 
as indicated in the text.  Glycemia was assessed through the analysis of tail vein blood 
prior to glucose injection/gavage and thereafter at 15, 30, 60, 90 and 120 min using a 
Freestyle glucose meter (Abbott). 
 In a separate study insulin secretion during IPGTTs was assessed in 13 week old 
male WT and KO mice.  Following a 6 hour fast, mice were anesthetized using isoflurane 
and blood samples were isolated from the retro-orbital venous plexus to obtain basal 
glucose and insulin levels.  Mice were allowed to recover for 15 min and were then 
injected with a 0.75 or 2.0 mg/kg body weight dose of glucose and the resulting glucose 
and insulin levels were assessed after 15 min.  Blood glucose levels were measured using 
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a glucose monitor (Freestyle, Abbott Diabetes Care Inc., Alameda, CA, USA) and plasma 
insulin levels were measured by RIA (Millipore, Billerica, MA, USA). 
 
Pancreas perfusion analysis of G6pc2 KO mice 
 In situ pancreas perfusions were performed on 14 week old mice following a 3 
hour fast according to the method of Bonnevie-Nielsen et al [206] with modifications 
[62, 207-209].  Briefly, mice were anesthetized and the superior mesenteric, hepatic, 
splenic, and right and left renal arteries were ligated and the aorta was tied off below the 
diaphragm so that the celiac trunk could be perfused with oxygenated Krebs-Ringer 
bicarbonate buffer containing 1% bovine serum albumin and 3% Dextran T70 
(AmershamBiosciences) at 1 ml/min.  Effluent was collected from the portal vein at 1 
min intervals and insulin secretion was measured by RIA by the Vanderbilt Diabetes 
Center Hormone Assay Core. 
 
Islet isolation, GSIS and arginine stimulated glucagon assays 
Islets were isolated from ~13 week old male G6pc2 mice (Chapter III), ∼20 week 
old male Slc30a8 mixed genetic background mice (Chapter IV) or ~18 week old Slc30a8 
C57BL/6J male and female mice (Chapter V) as described previously [209].  After 
isolation, islets were rinsed in three 12 ml changes of RPMI-1640 medium containing 
10% (v/v) FBS (foetal bovine serum), 100 units/ml penicillin, 100 μg/ml streptomycin 
and 11 mM glucose, and then cultured in 10 cm non-treated plates overnight at 37˚C.  
The next day islets were transferred into medium with 5 mM glucose and allowed to 
equilibrate for 1 h at 37˚C.  Following this equilibration period, 20-30 islet equivalents 
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(IEQs) were incubated in 5 ml of medium with 5, 11 or 16.7 mM glucose for 30 min at 
37ºC.  For the glucagon secretion assays, islets were cultured overnight as described 
above and, following the same equilibration period, were incubated in medium with 5 
mM glucose or 2 mM glucose with 20 mM arginine for 30 min at 37ºC.  At the end of the 
static incubations, islets were collected, washed and extracted in 0.2 ml of acid alcohol 
for 48 h at 4ºC.  The medium from the static incubations was centrifuged at 600g for 1 
min at 4ºC.  Islet extracts and static incubation media supernatants were stored at -80ºC 
until assayed for insulin or glucagon by radioimmunoassay (Millipore). 
 
Calcium assays 
 Islets were isolated from ~18 week old male WT and G6pc2 KO mice and 
cultured for two days in Krebs-Ringer buffer (2.5mM CaCl2, 119mM NaCl, 4.7mM KCl, 
10mM Hepes, 1.2mM MgSO4, 1.2 mM KH2PO4, 14.4mM glucose, pH 7.35) as 
previously described [210].  Prior to the experimental period, islets were transferred to 
calcium-free Krebs-Ringer buffer (1mM EGTA, 119mM NaCl, 4.7mM KCl, 10mM 
Hepes, 1.2mM MgSO4, 1.2 mM KH2PO4, 2mM glucose, pH 7.35) for 10 minutes.  
Thapsigargin experiments were then performed as previously described [211].  Briefly, at 
145 sec., 2μM thapsigargin was added to the media and calcium levels were measured by 
FURA-2 fluorescence. 
 
Immunohistochemical staining of Slc30a8 KO mice 
Pancreas tissue was fixed for 1 h in 4% (w/v) paraformaldehyde in PBS and 
embedded for paraffin sectioning (8 μm).  Primary antisera against insulin (guinea-pig 
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1:100; Dako), glucagon (mouse 1:100; Sigma) and somatostatin (rat 1:100; Abcam) were 
combined with a rabbit polyclonal antibody raised against a 102 amino acid C-terminal 
human ZnT-8 peptide (amino acids 268–369; used at 1:500) and were detected with 
species specific secondary antibodies conjugated to Cy2 (carbocyanine), Cy3 
(indocarbocyanine), Cy5 (indodicarbocyanine) and AMCA (aminomethylcoumarin) (all 
from Jackson Immunoresearch Laboratories). 
 
Analysis of islet number, size and cellular composition in Slc30a8 KO mice 
At least ten islets from a single or 20th consecutive pancreatic section were 
examined and scored from all groups of mice (n=6).  Images of individual islets co-
immunostained for insulin and glucagon were recorded with an Olympus BX51 
microscope using a Pixera 600 digital color camera and analyzed with Image-Pro Plus 
software (Media Cybernetics).  Briefly, the islet perimeter was marked with a pen tracer 
tool and Cy3 (indocarbocyanine)-stained glucagon-positive cells and Cy2 
(carbocyanine)-stained insulin-positive cells with associated nuclei (stained by Hoechst 
33258) were counted manually in a double-blind manner by two independent observers.  
Nuclei within the islet area that were not associated with either insulin- or glucagon-
positive cells were designated non-α/β-cells. 
Islet numbers and pancreatic area estimations were performed by scanning 
pancreatic sections immunostained for either insulin or glucagon using 
immunoperoxidase staining with diaminobenzidine as the pigment chromogen.  The 
slides were counterstained with haematoxylin and scanned into ScanScope GL (Aperio).  
Using Imagescope viewing software (Aperio), total pancreatic and all individual islet 
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areas (endocrine) visualized within the sections were quantified using a pen tracer tool.  
The percentage area was calculated as: 100 x (the sum of all individual islet areas)/(total 
area of the pancreatic section) and averaged (n=6 each group). 
 
Timm’s staining analyses in Slc30a8 KO mice 
The determination of zinc content in wild-type and Slc30a8 KO mouse pancreas 
was based on further modification of the revised Timm’s protocol described by Danscher 
et al. [212].  Briefly, pancreatic tissue sections (8 μm; frozen and paraffin) fixed in 4% 
(w/v) paraformaldehyde were placed on glass slides and immersed in 0.1% sodium 
sulfide in 0.15 M sodium phosphate buffer (pH 7.4) for 1 h in glass jars inside a chemical 
fume hood.  The slides were briefly rinsed in PBS and immersed in AMG 
(autometallography) developer [pH 3.8; 60 ml of gum arabic, 10 ml of sodium citrate 
(25.5 g of citric acid monohydrate+23.5 g of sodium citrate dihydrate in 100 ml of de-
ionized water), 15 ml of reducing agent (0.056% hydroquinone in de-ionized water at 
40˚C) and 15 ml of solution containing silver ions (0.008%silver lactate in de-ionized 
water at 40˚C) added just before use].  All glassware used for AMG development was 
rinsed in Farmer’s solution (10% sodium thiosulfate/10% potassium ferricyanide; 9:1) 
and warm water.  AMG development was carried out at room temperature (22˚C), in the 
dark and with gentle shaking.  The reaction was stopped after 45 min with 5% sodium 
thiosulfate solution for 10 min.  The slides were rinsed in warm water several times, 
counterstained with haematoxylin and eosin and permanently mounted. 
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Measurement of Slc30a8 islet zinc content 
Freshly isolated islets from WT and Slc30a8 KO mice were washed in Ca2+-free 
Hank’s balanced salt solution and frozen down at −80˚C in 20 islet aliquots.  Islet pellets 
were lysed by re-suspension in 1 ml of lysis buffer [1% Triton X-100 in 10 mM Tris/HCl 
(pH 7.4)].  The Zn2+ concentration in the lysate was measured using the Zn2+-sensitive 
fluorescent dye FluoZin-3 (Invitrogen).  In the presence of 1.181 μM FluoZin-3 the 
fluorescent signal at the emission peak (516 nm) was measured in the total sample lysate 
using a fluorometer (PTI Instruments).  The fluorescent signal was compared with a 
standard curve generated from serial dilutions of ZnSO4 in lysis buffer to obtain the 
lysate Zn2+ concentration and thus the Zn2+ content per islet.  As a normalization factor, 
the protein content per islet was measured in the total sample lysate using the BCA 
(bicinchoninic acid) protein assay (Pierce).  To minimize contaminating Zn2+, all 
solutions were made in double-distilled water (18.2 MΩ), avoiding the use of any 
glassware.  Blank samples were also prepared during the islet isolation to quantify any 
additional Zn2+ contamination. 
 
Insulin tolerance tests 
Insulin tolerance tests were performed on ~18 week old male and female Slc30a8 
mice (Chapter V) as described previously [213, 214].  Briefly, mice were weighed 
following a 4 hour fast and then allowed to recover for 1 hour prior to injection with a 
0.75 U/kg body weight dose of insulin.  Glycemia was assessed through the analysis of 
tail vein blood prior to insulin injection and thereafter at 7.5, 15, 22.5, 30, 37.5, 45 and 60 
min using a Freestyle glucose meter (Abbott). 
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Electron microscopy 
Primary fixation was performed by pancreas perfusion [207] with Karnovsky’s 
fixative (2.5% glutaraldehyde and 2% paraformaldehyde in 0.1 M sodium cacodylate 
buffer with 1% calcium chloride, pH 7.4).  Post fixation was performed with 1% osmium 
tetroxide, followed by dehydration with a graded series of ethanols, and embedding of 
tissue with Epon resin.  After islets were located on 500 nm sections, 60-70 nm sections 
were collected on grids, stained with uranyl acetate and lead citrate, and examined by 
transmission electron microscopy with a Philips CM-12 typically operated at 80 kV.  
Images were obtained with a 2k x 2k CCD AMT 542 digital camera. 
 
Analysis of SLC30 gene expression by quantitative RT-PCR in 9-23 week old human 
fetal pancreas and adult human islets 
SLC30 gene expression was analyzed using quantitative Real time PCR (Q-RT-
PCR).  Briefly, RNA was isolated from 9-23 week old fetal pancreas and adult human 
islets as previously described [215].  cDNA was then prepared from total RNA (1 mg) 
using the iScript cDNA synthesis kit (Bio-Rad Laboratories, Hercules, CA).  cDNA 
samples equivalent to 0.1 μg of the original RNA sample were used as templates for 
amplification in a 5' nuclease assay based system using FAM ® dye labeled Taqman 
MGB probes for selected SLC30 genes (Applied Biosystems, Foster City, CA, USA) and 
a 96-well ABI 7000 PCR system instrument.  The glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) gene was selected for sample normalization based on 
preliminary experiments with the ABI control plate (part number 430 9199).  The Cycle 
Threshold values (CT) were measured in triplicate and the samples were re-normalized to 
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the CT values from 9 week old pancreas samples (control group/calibrator) and data were 
quantified using the 2-ΔΔCT method (ABI User Bulletin #2). 
 
Statistical analyses 
Data were analyzed using a Student’s t test: two sample assuming equal variance.  
The level of significance was as indicated (two-sided test). 
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CHAPTER III 
 
ANALYSIS OF THE PHENOTYPE OF G6pc2 KNOCKOUT MICE ON A 
C57BL/6J GENETIC BACKGROUND 
 
Introduction 
 Numerous studies have investigated the biological importance of controlling 
fasting blood glucose (FBG) levels.  It has been well established that FPG is associated 
with increased risk for the development of type 2 diabetes [99].  In addition, a number of 
studies have indicated that even mild variations can have significant consequences on the 
risk of cardiovascular associated mortality.  For example, a study performed on a 
European male population demonstrated that a small increase in fasting blood glucose 
levels from just 90 mg/dl to between 99 and 108 mg/dl was associated with a 30% 
increase in the risk of cardiovascular associated mortality [97].  Conversely, a study 
performed in an Asian population indicated that a reduction in fasting blood glucose 
levels from 99 mg/dl to 90 mg/dl was associated with a 25% reduction in cardiovascular 
associated mortality [98].  Because of the apparent biological importance of tightly 
regulating FBG levels there has been tremendous interest in understanding how this 
parameter is controlled. 
Recent genome wide association (GWA) studies have shed light on this question 
by demonstrating that single nucleotide polymorphisms (SNP) within the G6PC2 gene 
were associated with variations in fasting glycemia [8, 216, 217].  These GWA study data 
are consistent with our previous study showing that global deletion of G6pc2 in mice on a 
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mixed, 129SvEv x C57BL/6J, genetic background results in a ~15% reduction in fasting 
blood glucose levels compared to wild type littermates [119].  These observations raise 
the key question as to how G6PC2 modulates FBG. 
The biological role of G6PC2 has remained unclear. While G6PC2 does 
hydrolyze G6P in vitro it does so with different kinetics than G6PC [45].  Specifically, 
G6PC2 exhibits both a lower KM (0.45 vs. 2.5 mM) and VMAX (32 vs. 2400 nmol/mg/min) 
than G6PC, raising the question as to whether G6P is a physiologically important 
substrate for this protein.  Because the pancreas does not significantly contribute to whole 
body glucose production, the biological purpose of a ß-cell specific glucose-6-
phosphatase is unknown. 
Indeed, even the question as to whether glucose-6-phosphatase activity is present 
in islets has been controversial, though the majority of studies have found that activity is 
detectable, but at a lower level than that found in liver [12, 44, 79, 218-220]. While there 
is now general agreement that glucose-6-phosphatase activity exists in pancreatic islets, 
the issue as to whether the level of activity is enough to result in significant glucose 
cycling and hence affect GSIS and therefore be of physiological significance, has been 
investigated by several groups [77, 78].  The use of G6pc2 KO mice represents an 
innovative approach to address the function of G6pc2 in vivo and definitively answer the 
question as to whether it accounts for the glucose-6-phosphatase activity and hence 
glucose cycling present in mouse islets. 
Despite this controversy over the importance of glucose-6-phosphatase activity in 
pancreatic islets we provide evidence here that G6PC2 opposes glucokinase and acts as 
an inhibitory component of the ß-cell glucose sensor thereby modulating the S0.5 of 
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glucose-stimulated insulin secretion (GSIS).  The data suggest that, in combination with 
glucokinase, G6PC2 creates a futile substrate cycle in which ATP is utilized thereby 
reducing the ATP:ADP ratio and hence insulin secretion.  A reduction in G6PC2 
expression therefore results in a leftward shift in the S0.5 of GSIS such that under fasting 
conditions FBG is reduced.  
While this model can explain the association between G6PC2 and FBG it also 
predicts that the leftward shift the S0.5 of GSIS resulting from a reduction in G6PC2 
expression would not be associated with a change in VMAX.  However, we show here that 
this model is incomplete because G6pc2 deletion is also associated with reduced maximal 
insulin secretion, an observation that is consistent with the GWA study data that also 
revealed that SNPs within the G6PC2 gene are not only associated with variations in 
fasting glycemia but also a reduction in insulin secretion during glucose tolerance tests 
[108].  We show here that sequestration of calcium into the ER, an important event in 
GSIS [221, 222], is impaired in the absence of G6PC2.  This observation explains the 
paradoxical GWA data and indicates that G6PC2 plays dual roles in the regulation of 
GSIS. 
 
Results 
Phenotypic characterization of fasted G6pc2 KO mice 
 G6pc2 KO mice were generated on a mixed 129/SvEvBRD x C57BL/6J genetic 
background as previously described [119] and subsequently backcrossed onto a pure 
C57BL/6J genetic background using a speed congenic breeding strategy.  Cross-breeding 
of heterozygous G6pc2 +/- mice resulted in a total of 325 mice where 85 were WT, 160 
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were +/- and 80 for KO, similar to the expected distribution for Mendelian inheritance.  
The ratio of males to females was 178:147.  Cross-breeding of KO mice indicated that 
deletion of G6pc2 does not affect fertility.   
 Table 3.1 summarizes the 6 hour fasted metabolic phenotype of the mice at 17 
weeks of age.  No significant changes were observed in body length or plasma insulin, 
triglycerides or glycerol in G6pc2 KO mice compared to WT littermates.  Fasting blood 
glucose was reduced in both male and female mice (16.4 and 14.4% respectively), 
consistent with our previous data obtained with mixed genetic background mice [119] 
and the findings of GWA studies [8, 93-95].  Fasting plasma cholesterol levels were also 
slightly but significantly reduced in both male and female KO mice (Table 3.1). This is 
consistent with the previously reported association between fasting glucose and 
cholesterol levels [223]. 
 
Analysis of GSIS in vivo during intraperitoneal glucose tolerance tests 
 Based on the reduction in FBG in G6pc2 KO mice we hypothesized that G6pc2 
acts as an inhibitory component of the beta-cell glucose sensor thereby modulating the 
S0.5 of glucose-stimulated insulin secretion (GSIS).  In this model G6pc2 would act in 
combination with glucokinase to create a futile substrate cycle in which ATP is utilized 
thereby reducing the ATP:ADP ratio and hence insulin secretion.  A reduction in G6pc2 
expression would therefore result in a leftward shift in the S0.5 of GSIS with no change in 
VMAX such that under fasting conditions, where insulin levels are identical regardless of 
the level of G6pc2 expression (Table 3.1), FBG would be reduced (Fig. 1.4). 
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 To directly assess the effect of G6pc2 on the S0.5 and VMAX of GSIS, we measured 
insulin secretion in response to varying glucose concentrations during insulin tolerance 
tests in vivo.  Following a 6-hour fast male WT and KO mice were injected with either a 
0.75 or 2.0 mg/kg body weight dose of glucose and the resulting glycemia was measured 
over a 90 or 120 min. period, respectively.  IPGTT experiments using the lower 
submaximal glucose dose were designed to detect the leftward shift in S0.5 while the 
higher dose was designed to detect changes in VMAX.  Injection with the 0.75 mg/kg dose 
of glucose resulted in a reduction in blood glucose at all time points in the KO mice with 
no change in glucose tolerance, indicating that KO mice live at a lower glucose threshold 
(Fig. 3.1A). We next directly measured insulin secretion following injection of 0.75 
mg/kg glucose (Fig. 3.1B).  Although not quite statistically significant (p=0.16), G6pc2 
KO mice display a trend towards enhanced insulin secretion.  These data are consistent 
with the concept that deletion of G6pc2 enhances insulin secretion at a given glucose load 
relative to WT mice and blood glucose is more efficiently lowered.  In contrast to the 
results from low dose injection of glucose, KO mice displayed impaired glucose 
tolerance following injection of 2mg/kg glucose (Fig. 3.1C).  We next directly measured 
insulin secretion following injection of 2.0 mg/kg glucose (Fig. 3.1D).  While insulin 
secretion did not differ significantly between WT and G6pc2 KO mice, insulin secretion 
in the KO mice was clearly insufficient to achieve normal glucose tolerance. 
These observations indicate that our original model of G6PC2 function, which 
was based solely on FBG data (Table 3.1), and which predicted that a reduction in 
G6PC2 expression would therefore result in a leftward shift in the S0.5 of GSIS with no 
change in VMAX is not correct (Fig. 1.4).  However, the G6pc2 KO mouse data are  
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Figure 3.1.  Analysis of glucose tolerance in G6pc2 KO mice in vivo.  Intraperitoneal 
glucose tolerance tests were performed on 6 hour fasted conscious wild type (closed 
symbols) and Slc30a8 KO (open symbols) male mice as described in Chapter II.  
Following the 6 hour fast, mice were injected with either 0.75 (Panels A and B) or 2.0 
(Panels C and D) mg/g body weight glucose in sterile PBS.  (A, C) Results show the 
mean glucose concentrations ± S.E.M. in wild type (mean age 13 weeks) and G6pc2 KO 
(mean age 13 weeks) animals.  (B,D) Insulin secretion was assessed as described in 
Chapter II.  Resulting mean glycemia and plasma insulin concentrations ± S.E.M. in wild 
type (mean age 13 weeks) and G6pc2 KO (mean age 13 weeks) animals. WT=wild type; 
KO=knockout. 
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consistent with equivalent experiments in humans showing that G6PC2 SNPs that are 
associated with elevated FBG (equivalent to WT mice) are associated with normal 
glucose tolerance but increased insulin secretion [108-110].  The mouse and human data 
suggest a new model (Fig. 3.2) in which, at low glucose concentrations, GSIS is 
enhanced in the absence of G6PC2 but at high glucose concentrations, GSIS is blunted in 
the absence of G6PC2. 
 
Analysis of GSIS from perfused pancreata of G6pc2 KO mice 
 To address the new model the effect of G6pc2 on the S0.5 and VMAX of GSIS was 
directly assessed by measuring insulin secretion in response to varying glucose 
concentrations from perfused pancreata in situ.  In response to submaximal 
concentrations of glucose, 6.5mM and 10mM, the pancreata of G6pc2 KO mice secreted 
~252% and ~90% more insulin, respectively (Fig. 3.3).  In addition, in G6pc2 KO mice, 
unlike WT mice, the maximal insulin response at 10 mM glucose was similar to that at 
16.7mM (Fig. 3.3).  In contrast, the pancreata of G6pc2 KO mice secreted about 33% less 
insulin in response to 16.7mM glucose.  These data suggest that there is a leftward shift 
in the S0.5 of GSIS but that there may be a reduction in VMAX, consistent with model 2 
(Fig. 3.2). 
 
Analysis of GSIS in islets isolated from G6pc2 KO mice 
 To directly assess the role of G6pc2 in islet function, GSIS was compared during 
static incubation in both freshly isolated islets and in isolated islets cultured overnight 
from male WT and KO mice.  To address our hypothesis that deletion of G6pc2 results in  
	   61	  
 
 
Figure 3.2.  Modified hypothesis of the effect of G6pc2 deletion in mice on GSIS 
dose-response curve.  G6pc2 is hypothesized to serve as a negative component of the β-
cell glucose sensor thus determining glycolytic flux.  Deletion of G6pc2 in mice is 
expected to result in a leftward shift in the dose-response curve of GSIS.  Data in Chapter 
III suggest that, in addition to the shift in S0.5, deletion of G6pc2 results in a reduction in 
the VMAX of GSIS. 
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Figure 3.3.  Analysis of GSIS from perfused pancreas experiments in situ in G6pc2 
KO mice.  Pancreas perfusion studies were performed on 3 hour fasted wild type (black 
line) and G6pc2 KO (gray line) animals at 14 weeks of age as described in Chapter II.  
Results show the mean glucose concentrations ± S.E.M.  WT=wild type; KO=knockout. 
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a leftward shift in the dose response curve of GSIS islets were stimulated with 11mM 
glucose, a submaximal dose.  GSIS from freshly isolated islets from KO mice did not 
differ from WT islets (Fig. 3.4A).  In contrast, however, KO islets that had been allowed 
to recover from the isolation process overnight displayed a ~2.4 fold enhanced GSIS at 
11mM glucose (Fig. 3.4B), consistent with a leftward shift in insulin secretion (Fig. 3.2).  
No differences in total insulin content were observed in these islets (Fig. 3.4C).  
Interestingly, a microarray analysis of WT islets indicated that freshly isolated islets lack 
the robust G6pc2 expression seen in islets following overnight culture (L. Pound and R. 
O’Brien, unpublished observations).  This may explain why we are unable to see a 
difference in GSIS in freshly isolated KO islets relative to WT islets.  
 To assess the VMAX of GSIS, islets were isolated, cultured overnight and then 
stimulated with 16.7mM glucose.  In contrast to submaximal glucose concentrations, 
GSIS did not differ at 16.7mM (Fig. 3.4D).  Again, there was no change in insulin 
content (Fig. 3.4E).  Interestingly, however, in islets isolated from G6pc2 KO mice, GSIS 
at 16.7mM glucose was actually blunted in comparison to the insulin response at 11mM.  
This result is consistent with model 2 in which the VMAX of GSIS is lowered in the 
absence of G6pc2 (Fig. 3.2). 
 
Analysis of ER calcium uptake in isolated islets from G6pc2 KO mice 
 While the G6pc2 KO mouse are consistent with the human GWA study data and a 
model (Fig. 3.2) in which reduced G6pc2 has both positive and negative effect on GSIS, 
the key remaining question is why the absence of G6pc2 would impair GSIS at high 
glucose concentrations.  Because SNPs in G6PC2 are not associated with altered insulin  
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Figure 3.4.  Analysis of GSIS and insulin content in islets isolated from G6pc2 KO 
mice.  Islets were isolated from wild type (WT) and G6pc2 knockout (KO) mice and then 
GSIS following stimulation with 11mM (Panels A, B) or 16.7 mM (Panel C) and insulin 
content (Panels C, E) were assayed as described in Chapter II.  Analysis was performed 
on either freshly isolated (Panel A) or overnight cultured (Panels B-E) islets.  Results are 
the mean insulin secretion ± S.E.M. from three to four islet preparations.  **p<0.01 
compared with wild type 11mM glucose. 
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sensitivity, altered pulsatility of insulin secretion has been invoked as a possible 
explanation for this paradoxical observation [110].  While altered pulsatility remains a 
possibility, we addressed an alternate explanation, namely that sequestration of calcium 
into the ER, an important event in GSIS [221, 222], may be impaired in the absence of 
G6pc2.  Thus, it has been suggested that generation of inorganic phosphate in the ER 
lumen, through the hydrolysis of G6P, may be important for the sequestration of calcium 
through the generation of calcium phosphate [224]. 
 To address this hypothesis, islets isolated from male WT and G6pc2 KO mice 
were treated with thapsigargin, a non-competitive inhibitor of sarco/endoplasmic 
reticulum calcium ATPases that is known to inhibit the uptake of calcium into 
intracellular stores, thus resulting in the emptying of calcium from these stores.  Islets 
isolated from G6pc2 KO mice showed an increased emptying of intracellular stores 
following treatment with thapsigargin (Fig. 3.5).  We interpret this to indicate that G6pc2 
KO mice have impaired retention of calcium in the ER. 
 
Discussion 
 In the present study, we have investigated the effect of a global deletion of G6pc2 
in vivo, a mouse model that is directly relevant to variations in FBG in humans.  We 
show that G6pc2 serves as a negative component of the ß-cell glucose sensor by 
modulating the S0.5 of GSIS.  Our data demonstrate that deletion of G6pc2 in C57BL/6J 
mice results in a leftward shift in the dose response curve for GSIS.  FBG levels are 
mildly reduced (Table 3.1) and both in situ pancreas perfusion studies (Fig. 3.3) as well 
as static islet cultures (Fig. 3.4B) indicate enhanced insulin secretion at submaximal  
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Figure 3.5.  Effect of the sarco/endoplasmic reticulum calcium ATPase inhibitor, 
thapsigargin, on ER retention of calcium.  Islets were isolated from wild type (WT) 
and G6pc2 knockout (KO) male mice at ~18 weeks of age and cultured for two days as 
described in Chapter II.  At 145 sec., 2μM thapsigargin was added to calcium-free media 
and calcium was assessed using the FURA-2 fluorescence method.  Results are the mean 
calcium concentration in the media ± S.E.M. from 10-20 islets from two mice per group.  
All time points from t=255 sec. to t=505 sec. are statistically significant. 
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glucose concentrations. Furthermore, IPGTTs using a sub-maximal 0.75 mg/g glucose 
concentration demonstrate that the G6pc2 KO mice live at a lower glucose set point (Fig. 
3.1A).  Surprisingly IPGTTs using a maximal 2.0 mg/g glucose concentration 
demonstrate impaired glucose tolerance (Fig. 3.1C), with inappropriately low insulin 
secretion (Fig. 3.1D).  Importantly, these observations are consistent with human GWA 
studies in which SNPs within the G6PC2 gene were found to associate with variations in 
fasting blood glucose levels [8, 93, 94] but paradoxically low insulin secretion during 
glucose tolerance tests [108-110].  We show here that the latter observation can be 
explained by an impairment in ER calcium sequestration in the G6pc2 KO mice (Fig. 
3.5). 
 A rise in intracellular calcium ions, resulting from the opening of voltage-gated 
calcium channels and the influx of calcium from the extracellular space and from the ER, 
is a key event in GSIS [221, 222].  The resulting calcium oscillations that occur 
contribute to pulses of insulin secretion and rely on rapid uptake and slow release of 
calcium by the ER [225].  Interestingly, it has been shown in liver microsomes that 
glucose-6-phosphatase activity is important for calcium uptake into the ER perhaps due 
to the production and buffering capacity of the inorganic phosphate ions [224].  Chen and 
colleagues, however, challenge this hypothesis because enhanced uptake of calcium into 
the ER is observed at phosphate concentrations below those at which significant 
buffering would be predicted to occur [226].  Rather, studies performed by Korge and 
Campbell suggest that phosphate ions may be capable of affecting calcium ATPase 
efficiency [227].  Our studies indicate that islets isolated from G6pc2 KO mice and 
treated with thapsigargin, a noncompetitive inhibitor of the sarco/endoplasmic reticulum 
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calcium ATPase, display an increased level of calcium released (Fig. 3.5).  Because 
phosphate production is important for retaining calcium in the ER and/or pumping 
calcium back into the ER, we interpret these data to mean that the G6pc2 KO mice have 
an impaired ability to maintain ER calcium levels and thus, higher levels of calcium are 
leaked from the cell following thapsigargin treatment.  These results may likely explain 
the paradoxical data obtained.  At submaximal glucose concentrations, extracellular 
calcium levels may be sufficient for proper GSIS and the loss of G6pc2 may then serve to 
increase relative ATP levels.  In contrast, at higher glucose concentrations, ER calcium 
may also be required for proper insulin secretion.  Thus, loss of ER calcium may result in 
a reduction in GSIS. 
Though the results from GWA studies [8, 93, 94, 108-110] would predict that 
complete loss of G6pc2 would have a more drastic effect on FBG and GSIS, we observe 
a relatively modest phenotype in the G6pc2 KO mice.  One possible explanation for this 
is that loss of G6pc2 during development resulted in compensatory responses such that 
the impact was blunted.  Future studies will assess the phenotype of G6pc2 KO mice 
using a conditional mouse model.  However, even if the severity of beta cell failure 
differed in the populations studied [93, 104, 228, 229], if variations in the G6PC2 gene 
universally contributed to type 2 diabetes susceptibility then this should have been 
apparent from the genetic analyses.  Interestingly, a recent study has challenged the 
relative importance of FPG to type 2 diabetes risk [101].  Abdul-Ghani and colleagues 
found that 1 hour plasma glucose following a GTT was actually a better predictor of type 
2 diabetes risk than FPG [101].  In fact, after controlling for 1 hour glycemia, FPG was 
no longer a significant predictor [101].  The authors suggest that the previous correlation 
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between FPG and type 2 diabetes risk is not due to the increase in FPG per se but is due 
instead to the correlation between FPG and 1 hour glycemia [101].  These data may 
explain why SNPs in the G6PC2 gene are associated with FPG and not type 2 diabetes in 
most populations.  In contrast, many other genes are in fact associated with both FPG and 
type 2 diabetes.  It seems more likely, however, that variations in these genes not only 
affect FPG but also affect 1 hour glycemia.  Their ability to influence the latter would 
then explain the association with type 2 diabetes. 
It seems likely that the conflicting genetic data indicate the importance of 
modifier genes such that G6PC2 is only linked with altered susceptibility to the 
development of type 2 diabetes in some populations and not others and that in the latter 
populations variations in G6PC2 expression and/or G6PC2 activity just alter the set point 
for GSIS rather than affecting the health of beta cells per se.  This may be explained in 
part by differences in the relative importance of G6PC2 for ER calcium uptake.  
However, it is important to note that the SNPs examined in genetic studies to date are 
predicted to have only small effects on G6PC2 expression [96].  Therefore, even though 
small elevation in G6PC2 expression may not be associated with risk of type 2 diabetes 
in some populations [104], this would not exclude the possibility that a larger elevation in 
G6PC2 expression may be associated with the risk of type 2 diabetes in all populations.  
Moreover, even if elevated G6PC2 expression was not a cause of type 2 diabetes in some 
populations per se, compounds that inhibited G6PC2 would not only be useful for 
lowering FBG and the risk of CAM, but, by reducing glucotoxicity, would also protect 
against beta cell failure and the onset of type 2 diabetes.  Importantly, a common problem 
with current glucose lowering therapies is that they fail to work over time [230].  
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Therefore, additional therapies are likely to be helpful.  Moreover, therapies that control 
FBG are likely to be especially helpful since treating elevated FBG, which obviously 
occurs at night, is particularly problematic in patients with diabetes [231]. 
 The findings of this study challenge the dogma that glucokinase is the ß-cell 
glucose sensor [73, 105, 232, 233].  It has been established that glucose phosphorylation 
rather than transport is the rate-limiting step in GSIS [106].  This conclusion is supported 
by studies demonstrating that overexpression of glucokinase increases GSIS [234] while 
overexpression of GLUT1 had no effect on GSIS [73] and a reduction in GLUT2 by 
>90% was required to affect GSIS [76].  Our findings demonstrate that G6pc2 can 
oppose glucokinase in the pancreatic ß-cell, which would be predicted to create a futile 
cycle in which ATP is utilized thereby reducing the ATP:ADP ratio.  Thus, we propose 
that G6pc2 is a fundamental inhibitory component of the ß-cell glucose sensor.  Future 
studies will examine the effect of G6pc2 deletion on islet metabolism to confirm this 
conclusion. 
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CHAPTER IV 
 
ANALYSIS OF THE PHENOTYPE OF Slc30a8 KNOCKOUT MICE ON A 
MIXED C57BL/6J x 129SvEv GENETIC BACKGROUND 
 
Introduction 
This chapter describes an examination of the effect of a global Slc30a8-null 
mutation in vivo, a mouse model that is directly relevant to type 2 diabetes susceptibility 
in humans.  The principal objectives were to identify the role of ZnT-8 in normal islet 
function.  The results are consistent with a role for ZnT-8 in islet function, although 
surprisingly not in whole-body glucose metabolism. 
As described in Chapter I, zinc is thought to complex with insulin hexamers and 
aid in proper insulin processing, storage and secretion.  Because the ZnT family is 
responsible for movement of zinc from the cytoplasm into intracellular vesicles and ZnT-
8 is highly expressed in the islet and, more specifically, the β-cell, we hypothesized that 
ZnT-8 serves as the primary provider of zinc to the insulin containing vesicles.  
Consistent with this hypothesis, overexpression of ZnT-8 in INS-1E insulinoma cells 
results in enhanced GSIS.  In addition, recent GWAS studies have shown that a 
nonsynonymous SNP within the SLC30A8 gene is associated with type 2 diabetes, 
gestational diabetes, proinsulin to insulin conversion and altered first phase insulin 
secretion, further supporting a role for ZnT-8 in islet function. 
The role of Znt-8 in vivo, however, had not been investigated.  Thus, we utilized 
the Slc30a8 KO mouse model in order to elucidate the role of ZnT-8 in in vivo insulin 
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secretion.  The studies described in this Chapter demonstrate that fasting insulin levels 
are reduced in both male and female mice and that GSIS is impaired in isolated KO 
mouse islets with no change in either fasting blood glucose or in glucose tolerance.  
These studies form the basis of the studies described in Chapter V where we further 
investigate the phenotype of Slc30a8 KO but on a pure C57BL/6J genetic background. 
 
Results 
Biochemical characterization of Slc30a8 KO mice 
The human SLC30A8 and mouse Slc30a8 genes contain eight exons ([235] and 
results not shown).  A modified mouse Slc30a8 allele, in which 135/147 bp of exon 3 and 
the first 10 bp of intron 3 were replaced by a LacZ/Neo cassette, was generated by 
homologous recombination in 129/SvEvBrd (Lex-2) ES (embryonic stem) cells (Fig. 
4.1A).  Deletion of exon 3 disrupts two putative ZnT-8 transmembrane domains [235].  
Correct gene targeting was confirmed by Southern blot (Fig. 4.1B) and PCR (results not 
shown) analysis prior to injection of ES cells into C57BL/6 (albino) blastocysts and 
subsequent generation of Slc30a8 heterozygous mice on a mixed 129/SvEvBrd x C57BL/6 
background.  Gene targeting and the generation of Slc30a8 heterozygous mice were 
performed by Lexicon Pharmaceuticals from whom we obtained the mice. 
To confirm that the targeting strategy had abolished Slc30a8 expression, 
immunohistochemical staining was performed on pancreas sections prepared from a 
Slc30a8 KO mouse and a WT littermate.  Fig. 4.1C shows that ZnT-8 was detected in 
both α- and β-cells in wild-type, but not Slc30a8 KO, mouse islets. 
	   73	  
 
 
	   74	  
 
 
Figure 4.1. Generation and biochemical characterization of Slc30a8 KO mice.  (A) 
Strategy used to generate Slc30a8 KO mice by homologous recombination in ES cells.  A 
schematic representation of the wild type murine Slc30a8 locus and the targeting 
construct are shown.  Exon 3 was replaced with a cassette containing an IRES (internal 
ribosome entry site), the LacZ gene and a TK (thymidine kinase)-neomycin selectable 
marker.  Correctly targeted clones were identified by Southern blot analysis using the 
indicated probes and were confirmed by PCR using the primers indicated.  The primers 
represented sequences in exon 3 (primer 1), intron 2 (primer 2), intron 3 (primer 4) and 
the Neo gene (Neo3a primer).  (B) Southern blot analysis of the Slc30a8 locus using 
genomic DNA extracted from the indicated targeted ES cell lines, or wild type ES cell 
genomic DNA, designated Lex-2, as a control, using 5’ and 3’ diagnostic probes (A).  
The sizes of the wild type locus, targeted allele and DNA markers are indicated.  Clone 
2H8 was used to achieve germline transmission.  (C) Immunohistochemical staining of 
wild type and Slc30a8 KO mouse pancreas with antisera raised against insulin, glucagon, 
somatostatin and ZnT-8 was performed as described in Chapter II.  Representative 
pictures (200x magnification) are shown. 
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The size and number of islets in Slc30a8 KO animals were indistinguishable from 
WT littermates, as were the relative numbers of α- and β-cells (Fig. 4.2).  Histological 
analysis of zinc content on frozen pancreatic sections using a modified Timm’s staining 
procedure that involves silver enhancement of metal sulfide precipitation showed that, in 
WT mouse pancreas, islets contained abundant zinc relative to the exocrine tissue (Fig. 
4.3A).  This contrasted with Slc30a8 KO mouse pancreas in which no difference was 
observed in Timm’s staining between islets and exocrine tissue, although gross islet 
morphology was preserved (Fig. 4.3A).  These results are consistent with analyses of zinc 
content in isolated islets using an assay that detects free and loosely bound zinc (Fig. 
4.3B).  Figure 4.3B shows that zinc content was markedly reduced in islets isolated from 
Slc30a8 KO mice relative to those isolated from WT mice. The concentration of zinc 
detected in WT islets was similar to that previously reported in the islet derived INS1 cell 
line [188]. 
 
Phenotypic characterization of Slc30a8 KO mice 
Genotype analysis of 383 3-week-old pups generated by crossbreeding 
heterozygous Slc30a8 mice demonstrated that 83 mice were WT, 203 were heterozygous 
and 97 were Slc30a8 KO, a distribution close to the expected pattern for Mendelian 
inheritance.  The ratio of male to female mice was 206:177.  Cross-breeding experiments 
revealed that both male and female homozygous Slc30a8 mice are fertile. 
The activity and behavior of Slc30a8 KO mice were indistinguishable from their 
WT and heterozygous littermates at all ages, from birth up to 1 year in age.  No gross 
anatomical changes were observed either externally or to major internal organs, and no  
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Figure 4.2.  Analysis of islet number, size and composition in Slc30a8 KO mice.  
Pancreas tissue was isolated from male wild type (WT) and knockout (KO) mice.  
Fixation, preparation of mouse pancreatic slices, immunohistochemical staining with 
antibodies raised to insulin and glucagon and quantitation of islet size, islet number and 
α- and β- cell numbers were then performed as described in Chapter II.  Results are 
presented as means ± S.E.M. 
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Figure 4.3.  Analysis of islet zinc content in Slc30a8 KO mice.  (A) A modified 
Timm’s staining protocol was used to assess zinc content in both frozen and paraffin 
pancreas sections prepared from male wild type and Slc30a8 KO mice as described in 
Chapter II.  Representative pictures (100x magnification) are shown.  (B) The zinc 
content in isolated islets was determined as described in Chapter II.  Results are the 
means ± S.E.M. (n=12).  *p<0.05 compared with wild type.  BG=background; WT=wild 
type; KO=knockout. 
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differences were seen in the weights or lengths of Slc30a8 KO compared with WT mice 
(Table 4.1). 
Table 4.1 summarizes metabolic parameters in these animals assayed at 16 weeks 
of age following a 6 h fast.  No marked changes in plasma cholesterol, triacylglycerol or 
glycerol were observed in either male or female Slc30a8 KO mice relative to WT animals 
(Table 4.1).  Blood glucose and glucagon concentrations were also unchanged in both 
male and female Slc30a8 KO mice relative to WT animals; however, a statistically 
significant difference in plasma insulin concentrations was observed (Table 4.1).  This 
result suggests that, although the absence of ZnT-8 might affect islet function, it has a 
limited effect on whole-body glucose metabolism.  In addition, since a statistically 
significant difference in plasma insulin concentrations was not observed between male or 
female Slc30a8 heterozygous mice relative to WT animals, this suggests that loss of a 
single Slc30a8 allele is insufficient to affect insulin secretion (Table 4.1).  Slc30a8 KO 
mice showed gender-related variation in the majority of these metabolic parameters that 
were in the same direction and of similar magnitude to the gender-related differences in 
WT mice.  Thus in males compared with females, insulin, triacylglycerols, cholesterol 
and glucose were all higher, whereas glucagon was lower (Table 4.1). 
Since some metabolic disturbances only become readily apparent under 
stimulatory rather than basal conditions intraperitoneal glucose tolerance tests were used 
to provide a measurement of dynamic islet function in vivo.  Following glucose injection 
(2 g/kg of body weight) blood glucose was assessed over a 120 min period (Fig. 4.4).  
The data show no impairment in glucose clearance between WT and Slc30a8 KO mice  
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Figure 4.4.  Analysis of glucose tolerance in Slc30a8 KO mice in vivo.  Intraperitoneal 
glucose tolerance tests were performed on overnight fasted conscious wild type (closed 
symbols) and Slc30a8 KO (open symbols) male mice as described in Chapter II.  Results 
show the mean glucose concentrations ± S.E.M. in wild type (n=30; mean age 20 weeks) 
and Slc30a8 KO (n=36; mean age 20 weeks) animals.  WT=wild type; KO=knockout. 
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(Fig. 4.4).  This result again suggests that, although the absence of ZnT-8 might affect 
insulin secretion it has a limited impact on whole-body glucose metabolism, at least 
under the conditions examined. 
 
Insulin secretion from Slc30a8 KO mouse islets 
To directly assess the impact of ZnT-8 on islet function, GSIS was compared in 
islets isolated from male WT and Slc30a8 KO mice in static incubations.  Figure 4.5A 
shows that insulin content did not differ between WT and Slc30a8 KO mouse islets, 
whereas Figure 4.5B shows that GSIS from Slc30a8 KO mouse islets was reduced ∼33% 
relative to that from WT mouse islets. 
 
Discussion 
In the present study we examine the effect of a global Slc30a8-null mutation in 
vivo, a mouse model that is directly relevant to type 2 diabetes susceptibility in humans.  
The study addresses the hypothesis that, based on GWA study data, changes in the 
activity or stability of the ZnT-8 protein may result in islet dysfunction, which contributes 
to the pathogenesis of type 2 diabetes.  The results indicate that deletion of the Slc30a8 
gene results in a mild metabolic phenotype on a mixed 129SvEvBrd x C57BL/6J 
background.  Plasma insulin is reduced in both male and female Slc30a8 KO mice 
following a 6 h fast (Table 4.1). Consistent with this observation, GSIS from isolated 
islets is impaired (Fig. 4.5B) and islet zinc content is markedly reduced (Fig. 4.3), 
although islet size, number and cellular composition are unaffected (Fig. 4.2).  These 
observations in Slc30a8 KO mice are consistent with the demonstration that  
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Figure 4.5.  Analysis of insulin content and GSIS in isolated Slc30a8 KO mouse 
islets.  Islets were isolated from wild type (WT) and Slc30a8 knockout (KO) mice and 
then insulin content (A) and GSIS (B) were assayed as described in Chapter II.  Results 
are the means ± S.E.M. from three to four islet preparations.  *p<0.05 compared with 
wild type 11mM glucose. 
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overexpression of ZnT-8 in INS-1 cells has the opposite effect, stimulating zinc 
accumulation and GSIS [188].  Although the loss of ZnT-8 function only has a mild 
effect it could be argued that this is nonetheless consistent with the small contribution of 
Slc30a8 mutations to type 2 diabetes risk, as reflected in the odds ratio of 1.12 [9, 103, 
189, 190].  However, that argument depends on a quantitative assessment of the 
deleterious nature of the identified SLC30A8 SNP on ZnT-8 function.  For example, if the 
SNP completely disables ZnT-8 then the low odds ratio would be consistent with the mild 
phenotype of Slc30a8 KO mice.  On the other hand, if the SNP only has a mild effect on 
ZnT-8 then a more dramatic phenotype would have been expected in Slc30a8 KO mice, 
with the caveats that the importance of ZnT-8 may vary between mice and humans and, 
in addition, compensatory events may have occurred in the Slc30a8 KO mice.  The latter 
concept is consistent with observations in vitro in INS-1E insulinoma cells.  Nicolson and 
colleagues demonstrated that while cells transfected with a ZnT-8 expression vector 
encoding the tryptophan variant display a significant reduction in zinc uptake, there is no 
significant change in GSIS [194].  We considered additional studies on these mixed 
genetic background mice that would have been designed to examine whether the absence 
of ZnT-8 affects glucose metabolism under conditions more favorable for the 
development of glucose intolerance, such as following high-fat feeding or in older 
animals.  However, we decided to postpone those studies until the KO allele was 
backcrossed onto the C57BL/6J genetic background, thus reducing variability between 
animals. 
Although the results indicate that ZnT-8 is important for normal islet function, 
surprisingly whole-body glucose metabolism appears unaltered based on an assessment 
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of fasting glucose levels (Table 4.1) and glucose tolerance tests (Fig. 4.4).  These 
observations suggest that ZnT-8 is not necessary for glucose homoeostasis, at least under 
the conditions examined.  There appear to be two possible explanations for the decrease 
in plasma insulin without a concomitant increase in blood glucose (Table 4.1).  There is a 
statistically significant decrease in plasma glucagon (∼20%) between male Slc30a8 
heterozygous and Slc30a8 KO mice, although not between Slc30a8 WT and Slc30a8 KO 
mice (Table 4.1).  If the latter simply reflects a lack of power to detect a small change in 
plasma glucagon, the former would imply that glucagon secretion is also impaired in 
male Slc30a8 KO mice.  In this event an offsetting decrease in both insulin and glucagon 
secretion could result in normal blood glucose.  Indeed, the insulin/glucagon ratios in 
individual animals were not statistically different between male WT and Slc30a8 KO 
mice (results not shown).  We realized that future experiments studying glucagon 
secretion from isolated islets would address this possibility but we also decided to 
postpone those studies until the KO allele was backcrossed onto the C57BL/6J genetic 
background, thus reducing variability between animals. 
In contrast to the males, in female mice there are no statistically significant 
differences in glucagon levels between groups (Table 4.1).  This suggested that there 
must be a different explanation for the reduced FBG in female mice without a 
concomitant change in insulin and glucagon levels.  One possibility was that there may 
be differences in insulin sensitivity between female WT and Slc30a8 KO mice.  This 
would be consistent with the results of post-hoc QUICKI calculations [236] suggesting a 
statistically significant difference in insulin sensitivity between female WT and Slc30a8 
KO mice (results not shown).  Such a difference could have arisen as an adaptive change 
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during development to compensate for low plasma insulin.  Alternatively, a difference in 
insulin sensitivity could arise if Slc30a8 were expressed in other tissues, specifically ones 
which directly or indirectly modulate insulin dependent glucose disposal.  Interestingly, 
Murgia et al. [237] have recently demonstrated that Slc30a8 is expressed at low levels in 
tissues other than islets.  We considered additional experiments to directly compare 
insulin sensitivity in female WT and Slc30a8 KO mice using hyperinsulinemic clamps 
but once again we decided to postpone those studies until the KO allele was backcrossed 
onto the C57BL/6J genetic background, thus reducing variability between animals.  
Finally, zinc is required not only for stabilizing the insulin crystal within the insulin 
storage granule, but may also be essential for the conversion of proinsulin to insulin 
[129].  Increased circulating pro-insulin is a feature of early type 2 diabetes and impaired 
glucose tolerance [238, 239] and in a group genetically at risk of developing type 2 
diabetes, the SLC30A8 allele was associated with reduced proinsulin into insulin 
conversion, although not insulin secretion [240].  Since proinsulin has only ∼3% of the 
potency of insulin [241], if proinsulin secretion was markedly increased in the female 
Slc30a8 KO mice this could also explain the reduced plasma insulin levels associated 
with unchanged blood glucose levels.   Unfortunately, commercially available assays for 
murine proinsulin were unavailable when these studies were performed. 
Chimienti et al. [235] had previously reported that ZnT-8 is only expressed in 
pancreatic islet β-cells, but using antiserum raised against a 102-amino-acid C-terminal 
human ZnT-8 peptide (amino acids 268–369) we found that ZnT-8 is also clearly 
expressed in α-cells (Fig. 4.1C).  This observation is consistent with the results of 
Gyulkhandanyan et al. [132] who examined ZnT-8 expression in dispersed islet cells.  
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The specificity of our antiserum was confirmed by the absence of staining in sections 
prepared from Slc30a8 KO mouse pancreas (Fig. 4.1C).  The hypothesis that glucagon 
secretion may be impaired in male Slc30a8 KO mice would therefore be consistent with 
the expression of ZnT-8 in α-cells (Fig. 4.1C).  However, the possibility also exists that 
glucagon secretion from α-cells has been indirectly affected by the absence of ZnT-8 in 
β-cells.  Indeed, although the mechanism(s) involved are disputed, zinc release from β-
cells inhibits glucagon secretion from α-cell [132, 177, 242]. 
The SNP that linked the human SLC30A8 gene to increased type 2 diabetes 
susceptibility [9, 103, 189, 190] is located in the C-terminus of ZnT-8 and represents a 
nonsynonymous polymorphism that changes the sequence of amino acid residue 325 
[235].  In theory this ZnT-8 variant could represent either a gain- or loss-of-function, but 
because overexpression of ZnT-8 enhances GSIS [188] and because deletion of the 
Slc30a8 gene in mice impairs GSIS (Fig. 4.5B) we would predict that this human 
sequence variant impairs ZnT-8 function.  Future experiments will be needed to address 
this hypothesis. 
 
	   87	  
CHAPTER V 
 
ANALYSIS OF THE PHENOTYPE OF Slc30a8 KNOCKOUT MICE ON A PURE 
C57BL/6J GENETIC BACKGROUND 
 
Introduction 
This chapter describes studies performed to directly follow up on those described 
in Chapter IV and to address the hypothesis that the absence of ZnT-8 results in impaired 
islet function and thereby contributes to type 2 diabetes.  The studies described in 
Chapter IV indicate that global deletion of Slc30a8 in mice results in a significant 
reduction in islet zinc content, a reduction in fasting plasma insulin levels and GSIS with, 
surprisingly, no change in fasting blood glucose levels or in glucose tolerance.  Though 
alterations in insulin secretion are consistent with the proposed role of zinc in the islet, 
the studies performed in vitro, and the GWA studies, the observation that both FBG and 
glucose tolerance were normal was unanticipated. 
Soon after the publication of the data described in Chapter IV, a number of other 
studies were published that also described the phenotype of Slc30a8 KO mice.  These 
studies all demonstrated a significant loss of zinc within the islet [194, 243, 244], 
supporting the proposed role of ZnT-8.  In contrast, however, the reported effect of 
Slc30a8 deletion on insulin secretion from isolated islets varied between these studies.  
Wijesekara et al demonstrated that GSIS was reduced in isolated Slc30a8 KO mouse 
islets, consistent with the results of our study, though the authors also reported no change 
in insulin secretion in KO mice during an IPGTT in vivo despite mildly impaired glucose 
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tolerance [243].  In contrast, Lemaire et al found no impairment in GSIS [244], while 
Nicolson et al reported an increase in GSIS from isolated Slc30a8 KO mouse islets, 
though this result varied with age and gender [194].  Surprisingly, however, this same 
study demonstrated, in young mice, a reduction in insulin secretion in Slc30a8 KO mice 
during an IPGTT as well as impaired glucose tolerance [194].  Finally, only one study 
examined plasma insulin levels following a 6 hour fast and found no change in a β-cell 
specific Slc30a8 KO mouse model [243].  The differences between these studies have 
been attributed to variations in the age and genetic background of the mice examined 
[245]; however, there were also marked differences in the numbers of mice analyzed in 
these different studies, which could be significant given the mild phenotypes reported 
[246]. 
Due to the variation in reported phenotypes, we sought to remove the conflicting 
effect of 129SvEv-specific modifier genes by examining the impact of Slc30a8 deletion 
in the context of the pure C57BL/6J genetic background.  Because binding of zinc to 
insulin is thought to be important for proper β-cell function, we predicted that a lack of 
granular zinc would again result in impaired insulin secretion in C57BL/6J Slc30a8 KO 
mice, consistent with observations in Slc30a8 KO mice on a mixed genetic background 
(Chapter IV).  Surprisingly, we find that, in contrast to the observations made with 
Slc30a8 KO mice on a mixed genetic background, on the C57BL/6J background only 
female Slc30a8 KO mice displayed a reduction in fasting plasma insulin.  Furthermore, 
despite this reduction in fasting plasma insulin there was no change in FBG, glucose 
tolerance or GSIS from isolated islets.  Our data therefore suggest that, despite the 
	   89	  
marked loss of zinc in islet insulin secretory granules, the absence of ZnT-8 does not 
have a substantial impact on normal mouse physiology. 
 
Results 
Generation of C57BL/6J Slc30a8 KO mice 
 Slc30a8 KO mice were initially generated on a mixed 129SvEvBrd x C57BL/6J 
genetic background (Chapter IV, [247]).  Using a speed congenic breeding strategy, mice 
were backcrossed onto a pure C57BL/6J genetic background.   
 Genotype analysis of 360 three week old pups generated by cross breeding 
C57BL/6J Slc30a8 heterozygous mice demonstrated that 88 mice were Slc30a8 WT, 184 
were Slc30a8 heterozygous, and 88 were Slc30a8 KO, a distribution close to the expected 
pattern for Mendelian inheritance.  The ratio of male to female mice was 201: 159.  Cross 
breeding experiments revealed that both male and female Slc30a8 KO mice are fertile.  
Furthermore, as with mice on a mixed genetic background, no gross anatomical or 
behavioral abnormalities were observed in Slc30a8 KO mice compared to WT or 
heterozygous mice on the C57BL/6J genetic background. 
 
Phenotypic characterization of male C57BL/6J Slc30a8 KO mice following a glucose 
challenge 
 On a mixed genetic background the effect of deleting the Slc30a8 gene was more 
apparent in male mice (Chapter IV, [247]), thus we initially analyzed the phenotype of 
male Slc30a8 KO mice on the pure C57BL/6J genetic background. 
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 We first performed IPGTTs to gain insight into islet function in vivo.  Following a 
6 hour fast, male mice were injected with glucose (2 mg/g body weight) and glycemia 
was measured over a 120 min period.  As in male Slc30a8 KO mice on a mixed genetic 
background (Chapter IV, [247]), no defect in glucose tolerance was observed (Fig. 5.1A).  
Furthermore, male Slc30a8 KO mice also displayed normal glucose tolerance when 
glucose was administered by gavage (Fig. 5.1B).  Thus, the results of glucose tolerance 
tests are consistent with the phenotype observed on a mixed genetic background (Chapter 
IV, [247]) and, most significantly, the conclusion that global deletion of the Slc30a8 gene 
has little effect on whole body glucose metabolism. 
 
Phenotypic characterization of fasted male C57BL/6J Slc30a8 KO mice 
 We next investigated the phenotype of male C57BL/6J Slc30a8 KO mice 
following a 6 hour fast. As with male Slc30a8 KO mice on a mixed genetic background 
(Chapter IV, [247]), no marked differences in body weight or length, fasting blood 
glucose or plasma, cholesterol, glycerol, triglycerides or glucagon were observed (Table 
5.1).  But surprisingly, male C57BL/6J Slc30a8 KO mice also displayed normal fasting 
plasma insulin levels (Table 5.1) in marked contrast to the ~50% reduction observed with 
male Slc30a8 KO on the mixed genetic background (Chapter IV, [247]).  This result 
suggests that the phenotype of male Slc30a8 KO mice is strongly dependent upon 
129SvEv-specific modifier genes.   
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Figure 5.1.  Analysis of glucose tolerance in male C57BL/6J Slc30a8 KO mice in 
vivo.  Intraperitoneal (Panel A) and oral (Panel B) glucose tolerance tests were performed 
on 6 hour fasted conscious C57BL/6J WT (closed symbols) and Slc30a8 KO (open 
symbols) male mice as described in Chapter II.  (A) Results show the mean glucose 
concentrations ± S.E.M. in WT (n=11; mean age ~20 weeks) and Slc30a8 KO (n=9; 
mean age ~20 weeks) animals.  (B) Results show the mean glucose ± S.E.M. in WT 
(n=16; mean age ~22 weeks) and Slc30a8 KO (n=9; mean age ~22 weeks) animals. 
A) 
B) 
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Insulin and glucagon secretion from male C57BL/6J Slc30a8 KO mouse islets 
 Even though fasting plasma insulin and glucose were unaltered in male C57BL/6J 
Slc30a8 KO mice (Table 5.1), we next analyzed GSIS in islets isolated from ~18 week 
old male mice so as to allow a direct comparison with the equivalent data obtained with 
islets isolated from Slc30a8 KO mice on a mixed genetic background.  Following 
overnight culture in 5 mM glucose, islets were incubated in either 5 mM or 11 mM 
glucose for 30 min.  No change in insulin content was observed in C57BL/6J Slc30a8 KO 
mouse islets (Fig. 5.2A), consistent with data obtained with islets isolated from Slc30a8 
KO mice on a mixed genetic background [247].  However, in marked contrast to the 
reduced GSIS observed using islets isolated from Slc30a8 KO mice on a mixed genetic 
background [247], islets from male C57BL/6J Slc30a8 KO mice displayed no change in 
GSIS (Fig. 5.2B).  These data are again consistent with the conclusion that the phenotype 
of male Slc30a8 KO mice is strongly dependent upon 129SvEv-specific modifier genes. 
 Because Slc30a8 is also expressed in α cells, we investigated both glucagon 
content and arginine-stimulated glucagon secretion in isolated male C57BL/6J Slc30a8 
KO mouse islets.  Despite the extensive literature describing a role for zinc secretion 
from β cells in the regulation of glucagon secretion from α cells [132, 177, 242], neither 
glucagon content (Fig. 5.2C) nor amino acid stimulation of glucagon secretion (Fig. 
5.2D) were altered. 
 
Phenotypic characterization of fasted female C57BL/6J Slc30a8 KO mice 
 Although the phenotype of male Slc30a8 KO mice observed on a mixed genetic 
background was not retained on the C57BL/6J background, female Slc30a8 KO mice on  
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Figure 5.2.  Analysis of insulin content, glucagon content, GSIS and arginine-
stimulated glucagon secretion in male C57BL/6J Slc30a8 KO mouse islets in situ.  
Islets were isolated from male C57BL/6J WT and Slc30a8 KO mice and then insulin 
content (Panel A), GSIS (Panel B), glucagon content (Panel C) and arginine-stimulated 
glucagon secretion (Panel D) were assayed as described in Chapter II.  Results show the 
mean data ± S.E.M. from 3 islet preparations isolated from ~18 week old male mice.  *, 
p<0.05 versus WT 11mM glucose. 
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the mixed genetic background also displayed reduced fasting insulin levels [247].  We 
therefore assessed the phenotype of the female C57BL/6J Slc30a8 KO mice following a 6 
hour fast at ~16 weeks of age (Table 5.1).  As with the males, female C57BL/6J Slc30a8 
KO mice displayed no marked differences in body weight or length or fasting plasma 
cholesterol, glycerol, triglycerides or glucagon.  But, consistent with observations on the 
mixed genetic background, female C57BL/6J Slc30a8 KO mice displayed a marked 
reduction (~20%) in fasting plasma insulin levels with no change in fasting blood glucose 
levels (Table 5.1), though the magnitude of this reduction was somewhat greater in 
female Slc30a8 KO mice on the mixed genetic background (~30%) [247].  This result 
implies that, in contrast to male mice, the phenotype of female Slc30a8 KO mice is less 
dependent upon the influence of 129SvEv-specific modifier genes. 
 
Phenotypic characterization of female C57BL/6J Slc30a8 KO mice following a glucose 
challenge 
 We next determined whether the reduction in fasting plasma insulin in female 
C57BL/6J Slc30a8 KO mice resulted in impaired glucose tolerance.  Both intraperitoneal 
(Fig. 5.3A) and oral (Fig. 5.3B) glucose tolerance tests indicated that glucose tolerance is 
normal in female C57BL/6J Slc30a8 KO mice.  A similar observation was previously 
made with male Slc30a8 KO mice on a mixed genetic background in which a marked 
reduction in fasting plasma insulin was not associated with a change in glucose tolerance 
[247]. 
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Figure 5.3.  Analysis of glucose tolerance in female C57BL/6J Slc30a8 KO mice in 
vivo.  Intraperitoneal (Panel A) and oral (Panel B) glucose tolerance tests were performed 
on 6 hour fasted conscious C57BL/6J WT (closed symbols) and Slc30a8 KO (open 
symbols) female mice as described in Chapter II.  (A) Results show the mean glucose 
concentrations ± S.E.M. in WT (n=6; mean age ~20 weeks) and Slc30a8 KO (n=8; mean 
age ~20 weeks) animals.  (B) Results show the mean glucose concentrations ± S.E.M. in 
WT (n=9; mean age ~22 weeks) and Slc30a8 KO (n=12; mean age ~22 weeks) animals. 
A) 
B) 
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Insulin secretion from female C57BL/6J Slc30a8 mouse islets 
 In male Slc30a8 KO mice on a mixed genetic background, although glucose 
tolerance was not altered, the marked reduction in fasting plasma insulin was associated 
with impaired GSIS [247].  We therefore investigated whether the reduction in fasting 
plasma insulin in female Slc30a8 KO mice was also associated with impaired GSIS.  
Islets were isolated from ~18 week old female C57BL/6J WT and Slc30a8 KO mice and 
insulin content and secretion were measured following static incubations in either 5 mM 
or 11 mM glucose.  No differences in insulin content between WT and KO islets were 
observed (Fig. 5.4A).  And surprisingly, despite the reduction in fasting insulin levels, 
GSIS in female C57BL/6J Slc30a8 KO mouse islets did not differ from WT islets (Fig. 
5.4B).  Thus, in contrast to male Slc30a8 KO mice on the mixed genetic background, 
reduced fasting insulin levels were not associated with reduced GSIS from isolated 
female C57BL/6J Slc30a8 KO mouse islets. 
 
Analysis of the mechanism by which fasting plasma insulin is reduced in female 
C57BL/6J Slc30a8 KO mice with no change in glucose tolerance 
 To address the issue as to how fasting plasma insulin levels could be altered with 
no change in fasting blood glucose, we considered three possibilities.  First, it was 
possible that female C57BL/6J Slc30a8 KO mice would also manifest a corresponding 
reduction in fasting plasma glucagon levels, such that the KO mice are simply living at a 
different metabolic equilibrium.  However, no significant difference in fasting plasma 
glucagon levels was observed (Table 5.1).  This is consistent with the female Slc30a8 KO  
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Figure 5.4.  Analysis of insulin content and GSIS in female C57BL/6J Slc30a8 KO 
mouse islets in situ.  Islets were isolated from female WT and Slc30a8 KO mice and 
then insulin content (Panel A) and GSIS (Panel B) were assayed as described in Chapter 
II.  Results show the mean data ± S.E.M. from 6 islet preparations isolated from ~18 
week old female mice. 
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mice on a mixed genetic background in which a reduction in fasting insulin was not 
associated with a change in fasting glucagon [247]. 
 Second, because it has been proposed that zinc is important for proinsulin to 
insulin conversion [129] and, in humans, variations in the SLC30A8 gene are associated 
with impaired proinsulin conversion [240], it was conceivable that increased proinsulin 
levels may have compensated for the reduction in insulin secretion.  Proinsulin can bind, 
albeit with low affinity relative to insulin, to the insulin receptor and thus activate insulin 
signaling pathways [241].  However, fasting proinsulin levels were unchanged in female 
Slc30a8 KO mice following a 6 hour fast (Table 5.1), though the difference between WT 
and KO was close to significance (p<0.06).  Interestingly, male C57BL/6J Slc30a8 KO 
mice displayed a significant reduction in proinsulin levels following a 6 hour fast (Table 
5.1), suggesting that insulin processing is altered, though not sufficiently to lead to a 
reduction in fasting glucose or insulin levels.  However, even this effect appears subject 
to the influence of modifier genes since it is not observed in male Slc30a8 KO mice on a 
mixed genetic background (Fig. 5.5). 
 Finally, we considered the possibility that insulin sensitivity was enhanced in the 
female C57BL/6J Slc30a8 KO mice to offset the reduction in fasting insulin secretion.  
Such a change could have arisen either indirectly, as an adaptive compensation to offset 
the reduction in fasting insulin secretion, or directly as a consequence of the absence of 
ZnT-8 in several other tissues where it is expressed at low levels [237].  Insulin tolerance 
tests, however, indicated that neither female (Fig. 5.6A) nor male (Fig. 5.6B) C57BL/6J 
Slc30a8 KO mice display altered insulin sensitivity. 
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Figure 5.5.  Analysis of plasma proinsulin in mixed genetic background Slc30a8 KO 
mice in vivo.  At 16 weeks of age mice were fasted for 5 hours and then weighed.  One 
hour later mice were anesthetized, their length was measured and blood isolated.  Plasma 
proinsulin levels were determined as described in Chapter II.  Results represent mean 
data ± S.E.M. obtained from the indicated number of animals in parentheses. 
	   101	  
 
 
Figure 5.6.  Analysis of insulin sensitivity in C57BL/6J Slc30a8 KO mice in vivo.  
Insulin tolerance tests were performed on 5 hour fasted conscious C57BL/6J WT (closed 
symbols) and Slc30a8 KO (open symbols) female (Panel A) and male (Panel B) mice as 
described in Chapter II.  (A) Results show the mean glucose concentrations ± S.E.M. in 
WT (n=8; mean age ~18 weeks) and Slc30a8 KO (n=8; mean age ~18 weeks) animals.  
In these groups of mice the initial glucose concentration at time zero was higher in KO 
mice (142.6 ± 6.1 vs 120.8 ± 4.9 mg/dl; p<0.02).  (B) Results show the mean glucose 
concentrations ± S.E.M. in WT (n=11; mean age ~18 weeks) and Slc30a8 KO (n=6; 
mean age ~18 weeks) animals.  In these groups of mice the initial glucose concentration 
at time zero was not different between WT (153.0 ± 4.8 mg/dl) and KO (165.0 ± 2.3 
mg/dl) mice. 
A) 
B) 
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Analysis of C57BL/6J Slc30a8 KO mouse islets using electron microscopy 
 Previous studies [194, 243, 244] have reported markedly altered islet secretory 
granule morphology in Slc30a8 KO mice, which seems at odds with the mild metabolic 
phenotype.  We therefore re-examined islet beta cell secretory granule morphology in the 
C57BL/6J Slc30a8 KO mice.  The results demonstrate that female C57BL/6J Slc30a8 
KO granules are indistinguishable from control mice (Fig. 5.7).  The size and shape of 
both the granules and the electron dense cores did not appear to differ from control islets 
(Fig. 5.7).  This suggests that female C57BL/6J Slc30a8 KO mice have normal insulin 
crystallization and packaging.  In the published studies Nicholson et al. [194] and 
Wijesekara et al. [243] both fixed isolated islets whereas Lemaire et al. [244] fixed intact 
pancreas by immersion.  In contrast, our fixation method involved the more challenging 
fixation of the pancreas by vascular perfusion in situ.  This method has the advantage of 
minimizing perturbations to cell structure by rapidly and uniformly delivering the fixative 
to the tissue using the animals’ own vasculature.  We speculate that perfusion of the 
fixative results in the maintenance of true islet architecture, which may explain the 
differences between our results and published observations. 
 
Analysis of pancreatic SLC30 developmental expression 
 The association between SLC30A8 and susceptibility to type 2 diabetes appears at 
odds with the very mild phenotype of Slc30a8 KO mice.  While there are multiple 
possible explanations for this apparent inconsistency we considered the possibility that 
ZnT-8 may play a more important role during islet development in humans than mice.  
Indeed, islet development appears significantly different between humans and mice with  
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Figure 5.7.  Analysis of insulin secretory granule structure in C57BL/6J Slc30a8 KO 
mice.  Islets were fixed in situ using pancreas perfusion and electron microscopy was 
then performed on pancreas sections as described in Chapter II. 
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the human equivalent of a mouse endocrine secondary transition not evident, either in 
terms of morphology or in dramatic changes in endocrine-specific transcriptional 
regulators [215].  We have previously shown that a marked increase in islet Slc30a8 gene 
expression is observed between e15.5 and e17.5 in mice whereas insulin expression is 
already clearly evident at e15.5 [248].  In humans insulin transcripts are already present 
at 9-10 weeks and only increase ~50% further by 23 weeks, commensurate with the 
expansion of endocrine cell volume [215].  Figure 6 shows that SLC30A8 expression 
increases markedly between 9 weeks and 23 weeks, indicating that in humans as in mice, 
high insulin expression precedes that of SLC30A8.  Figure 5.8 also shows that SLC30A8 
is the major SLC30 isoform in human islets, as it is in mice [194].  These observations do 
not support the concept of a dramatic difference between mice and humans with respect 
to a role for ZnT-8 during development.  
 
Discussion 
 Our data demonstrate that the consequences of Slc30a8 gene deletion in mice are 
both gender- and genetic background-specific.  A decrease in fasting insulin was 
observed in female Slc30a8 KO mice on both the pure C57BL/6J and mixed genetic 
backgrounds whereas this difference was only observed in male Slc30a8 KO mice on the 
mixed genetic background (Table 5.1) [247].  In male Slc30a8 KO mice on a mixed 
genetic background this decrease in fasting insulin was associated with reduced GSIS 
from isolated islets [247] whereas in female Slc30a8 KO mice on the C57BL/6J genetic 
background it was not (Fig. 5.4B).  While this may indicate that a defect that exists in 
female Slc30a8 KO islets in vivo is not maintained in isolated islets, this apparent  
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Figure 5.8.  Normalized expression of selected SLC30 genes by quantitative RT-PCR 
in 9-23 week old human fetal pancreas and adult human islets.  Data in triplicate 
(mean ± S.E.M.) is normalized to endogenous GAPDH and quantified and expressed 
relative to 9 week old fetal samples.  SLC30A2 expression was detectable in the fetal 
pancreas from 19 weeks. *p<0.05 from 9 weeks for SLC30A8 (black bars). 
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discrepancy more likely simply reflects the fact that the decrease in fasting insulin in 
male Slc30a8 KO mice on a mixed genetic background is much greater than seen in 
fasting C57BL/6J female Slc30a8 KO mice (50% vs 20%; Ref. [247] and Table 5.1).  
Therefore many more isolated islet preparations would have to be studied to uncover the 
expected small change in GSIS, which is not feasible given the inherent variability 
between isolated islet preparations.  Most strikingly, no change in glucose tolerance was 
observed in male or female Slc30a8 KO mice on either a mixed [247] or pure (Figs. 5.1 
& 5.3) genetic background.  Overall these results suggest a minor role for Slc30a8 and β 
cell zinc in the regulation of glucose metabolism.  The small alteration in proinsulin 
secretion in male Slc30a8 KO mice does suggest a role for zinc in insulin processing 
(Table 5.1), though even this effect is also influenced by genetic background (Fig. 5.5). 
 The conclusion from this study that ZnT-8 plays a minor role in the regulation of 
glucose metabolism is consistent with our previous conclusion [247] and that of Lemaire 
et al. [244].  In contrast, Nicholson et al. [194] observed an impairment in glucose 
tolerance and insulin secretion in Slc30a8 KO mice during IPGTTs.  All these studies 
were performed in mice with a global Slc30a8 deletion on a mixed genetic background.  
In more recent studies in which the Slc30a8 gene was deleted specifically in beta cells, 
the same group observed a more mild impairment in glucose tolerance during OGTTs but 
this was associated with no impairment of insulin secretion [243].  In humans the 
rs13266634 polymorphism in the SLC30A8 gene has been linked to not only type 2 
diabetes but also impaired glucose tolerance [193], impaired proinsulin to insulin 
conversion [240] and reduced first phase insulin secretion [249].  It is therefore apparent 
that a change in ZnT-8 function in humans leads to an increased susceptibility to the 
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development of impaired β-cell function, making it easy to envisage how a functionally 
impaired β-cell would be more prone to the action of other environmental factors that 
promote β-cell failure and lead to type 2 diabetes [250].  In contrast, overall, the studies 
of ZnT-8 function in mice fail to clearly establish why this protein would be associated 
with altered susceptibility to the development of type 2 diabetes.  There is clear evidence 
for altered zinc levels [194, 243, 244, 247], GSIS [243, 247] and proinsulin conversion 
(Fig. 5.5; Ref. [243]) in these mouse models but the effects are influenced by gender and 
modifier genes and there is no consistent change in glucose tolerance.  Potential 
explanations for this difference between the human and mouse data include the 
possibility that ZnT-8 is more important for islet function in humans than mice or that 
mice can more readily compensate for changes in ZnT-8 expression.  With respect to the 
latter, future studies in which Slc30a8 is deleted in adult mice rather than during 
development might be informative as might studies in older mice.  In contrast to many 
mouse models [251], high fat feeding does not appear to unmask a diabetic phenotype in 
Slc30a8 KO mice, though only 2 mice were studied [194]. 
 The physiological basis for observed reduction in fasting insulin levels in female 
mice on the pure C57BL/6J background (Table 5.1), and both male and female mice on 
the mixed genetic background [247], without a concommitant change in fasting glucose 
levels remains unknown.  This phenomenon does not appear to be explained by altered 
insulin sensitivity (Fig. 5.6) or a major change in proinsulin secretion (Table 5.1).  The 
results do provide weak evidence for an offsetting change in glucagon secretion.  Thus, 
though no statistically significant changes in fasting glucagon levels were observed in 
male or female C57BL/6J Slc30a8 KO mice, female C57BL/6J Slc30a8 KO mice do 
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display a trend toward reduced glucagon secretion (Table 5.1).  Furthermore, this trend is 
also observed in male mice on a mixed genetic background and reaches significance in 
the comparison of KO and heterozygous mice, presumably due to the larger sample size 
[247].  This might suggest that our inability to detect a difference in fasting glucagon 
levels in the aforementioned groups may be due to a lack of power.  The hypothesis that 
glucagon secretion is impaired in Slc30a8 KO mice would be consistent with the 
demonstration that ZnT-8 is expressed in α cells [247].  In addition, it has been 
previously shown that the zinc released from the insulin hexamers following insulin 
release by the β cell can affect glucagon secretion by the α cell, though the mechanism 
by which it does this is disputed [132, 177, 242].  This suggests that deletion of Slc30a8 
could affect glucagon secretion from α-cells by both direct and indirect mechanisms.  
However, in fasting female Slc30a8 KO mice on a mixed genetic background there is no 
evidence for a trend toward reduced glucagon secretion despite the clear reduction in 
fasting insulin [247], which implies that altered glucagon secretion cannot explain the 
normal fasting glucose levels in the presence of reduced fasting insulin levels. 
 In vitro studies have suggested that the rs13266634 non-synonymous SNP within 
the SLC30A8 gene, which results in an arginine to tryptophan conversion at the C-
terminus of the protein, alters the ZnT-8 dimer interface and thereby affects zinc uptake 
and accumulation into granules [194].  Cells transfected with a ZnT-8 expression vector 
encoding the tryptophan variant show a reduction in zinc uptake and consequent granular 
zinc levels as compared to cells transfected with a ZnT-8 expression vector encoding the 
arginine variant [194].  Furthermore, deletion of Slc30a8 results in a marked reduction in 
islet zinc content [194, 243, 244, 247].  Given the postulated critical role of zinc in 
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insulin secretion [243], it is logical that SNPs within the SLC30A8 gene would be 
associated with impaired β-cell function.  It was surprising, therefore, given the decrease 
in zinc observed in Slc30a8 KO islets, that the observed phenotype in both our study and 
in other reports was mild and did not result in significant perturbations in whole body 
glucose metabolism.  Consistent with observations in Slc30a8 KO mice in vivo, no 
significant differences between the two ZnT-8 variants described above were observed in 
tissue culture studies with respect to their affect on GSIS, despite significant differences 
in their effects on granular zinc levels [194]. 
 Overall, these observations suggest that the complete absence of ZnT-8 is not 
enough to lead to impaired glucose tolerance in mice.  It is conceivable, however, that 
additional disturbances are required to unmask a more significant phenotype in Slc30a8 
KO mice, such as the presence of mutations in other type 2 diabetes-associated genes or 
zinc-deficient diets.  Future studies will address these possibilities.  In addition, the 
results suggest that either very low levels of zinc are sufficient for proper insulin 
crystallization and secretion or that zinc is not as important for insulin secretion as 
previously hypothesized.  Indeed, guinea-pig insulin lacks a histidine residue in the B10 
position of the molecule, which normally binds zinc in hexamer formation, and the zinc 
content of guinea pig islets is very low compared to mice and rats [167]. 
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CHAPTER VI 
 
SUMMARY AND FUTURE DIRECTIONS 
 
Thesis Summary 
This dissertation describes experiments that provide insight into the roles of both G6pc2 
and ZnT-8 in vivo.  Both the G6PC2 and SLC30A8 genes had been previously identified 
in GWA studies to be associated with FPG levels and type 2 diabetes, respectively.  Thus, 
our studies sought to provide evidence that the identified SNPs affect the gene in which 
they are located, as opposed to affecting expression of a neighboring gene, as well as to 
better understand how changes in expression of these genes would result in altered 
susceptibility to elevated FPG levels and type 2 diabetes.  Using static islet incubations, 
IPGTTs and pancreas perfusion studies, we demonstrated that deletion of G6pc2 on the 
pure C57BL/6J genetic background results in a leftward shift in the dose-response curve 
of GSIS, resulting in enhanced insulin secretion at submaximal glucose concentrations.  
Surprisingly, however, we also demonstrated that the phenotype appears to be more 
complex at higher glucose concentrations. G6pc2 KO mice displayed impaired glucose 
tolerance, perhaps as a result of impaired calcium resequestration in the ER.  In addition, 
while high fat feeding did exacerbate the phenotype, this effect was both genetic 
background and gender dependent. 
Both male and female Slc30a8 KO mice display reductions in fasting plasma 
insulin levels with no change in FBG concentrations on the mixed C57BL/6J X 129SvEv 
genetic background.  Male mice also display impaired GSIS during static islet 
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incubations but have normal glucose tolerance during an IPGTT.  We sought to clarify 
this phenotype further on the C57BL/6J genetic background.  In this case, female, but not 
male, mice display reduced fasting plasma insulin levels with no change in FBG.  Female 
Slc30a8 KO mice, however, exhibited normal glucose tolerance following either an 
IPGTT or an OGTT and islets isolated from these mice showed no change in GSIS in 
static islet incubations.  The female mice do, however, display reductions in proinsulin 
levels, indicating that these mice possess an insulin processing defect. 
In summary, the studies described here attempted to provide insight into how two 
genes identified in the GWA studies, G6PC2 and SLC30A8, may be contributing to FPG 
and type 2 diabetes, respectively.  The data derived from the study of G6pc2 KO mice 
strongly support a role for G6pc2 in the regulation of FBG.  In contrast, the data derived 
from the study of Slc30a8 KO mice revealed that, depending on the genetic background, 
insulin secretion can be unaffected despite a major reduction in granule zinc content.  
Furthermore, these KO mouse studies did not uncover the reason why the SLC30A8 gene 
is associated with risk for the development of type 2 diabetes. 
Though the phenotype of the G6pc2 KO mice is consistent with the results of the 
GWA studies, the Slc30a8 KO mouse phenotype differs from what would be expected 
based on observations in humans.  This may be explained by the fact that the GWA study 
approach only indicates altered susceptibility to the given condition.  Thus, the variant 
identified within the SLC30A8 gene may not individually lead to impaired β-cell 
function.  Rather, it is likely that a combination of additional risk variants and 
environmental components may play an important role in the contribution of rs13266634 
to type 2 diabetes.  This may, therefore, explain the discrepancy between the human 
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GWA studies and the observed phenotype in the Slc30a8 KO mice.  Future studies will 
address this possilibity.  Alternatively, it is also possible that rather than merely serving 
to alter SLC30A8 function, the rs13266634 risk variant may instead result in protein 
misfolding and, subsequently, ER stress. 
 
Further studies to elucidate the role of G6pc2 
These studies have begun to clarify the biological role of both proteins; however, 
a number of additional studies could be performed to further clarify their function in vivo.  
Though initial attempts by both our laboratory [49] and by Chou and colleagues [252] to 
demonstrate glucose-6-phosphatase activity of G6PC2 and G6pc2 were unsuccessful, 
Petrolonis and colleagues were able to successfully demonstrate that G6PC2 could 
hydrolyze G6P [45].  In collaboration with John Hutton, we have since modified the 
assay conditions and have demonstrated that both G6PC2 and G6pc2 display hydrolytic 
activity (Fig. 1.2).  Thus, using these novel conditions in which cells are mildly 
permeabilized, it will be important, first and foremost, to demonstrate that while we can 
detect glucose-6-phosphatase activity in islets isolated from WT mice, glucose-6-
phosphatase activity is either reduced or absent in islets isolated from G6pc2 KO mice. 
In addition to demonstrating altered glucose-6-phosphatase activity in islets 
isolated from WT and KO mice, the use of WT and KO islets will definitively answer 
whether G6pc2 is responsible for glucose cycling in the islet.  In collaboration with Dr. 
Jamey Young we can use a stable isotope strategy [253] to more accurately assess 
whether there is a decrease in glucose cycling in the knockout islets. 
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Finally, to confirm the aforementioned studies as well as the data described in 
Chapter III, it will be important to measure additional parameters in isolated islets such as 
G6P, ATP and NAD(P)H.  Because overexpression of glucokinase has been shown to 
result in increased intracellular levels of both G6P and ATP along with a leftward shift in 
the S0.5 of GSIS [254, 255] and because deletion of G6pc2 results in a similar leftward 
shift in the S0.5, we would expect to observe elevated G6P and ATP levels in the G6pc2 
KO mouse islets.  Loss of G6pc2 would be predicted to leave phosphorylation of glucose 
unopposed and would eliminate the futile cycle and, therefore, the consumption of ATP.  
Furthermore, intracellular NAD(P)H levels would be predicted to be elevated in G6pc2 
KO mouse islets due to increased glucose metabolism, changing in parallel with 
enhanced insulin secretion at low glucose concentrations. 
We have also considered the possibility that loss of G6pc2 during development 
results in compensatory responses such that the effect of the deletion is minimized.  For 
this reason, it will be interesting to perform similar experiments to those described in 
Chapter III using an inducible gene targeting approach in the mouse with the Cre/loxP 
system in order to remove G6pc2 during adulthood. 
 
The role of G6pc2 during exercise: preliminary data and future directions 
Although initially deletion of G6pc2 had appeared beneficial and thus the 
evolutionary conservation of G6pc2 function had been unclear, the importance of G6pc2 
function became apparent at high glucose levels.  Our data suggest that G6pc2 activity 
may be necessary for the resequestration of ER calcium following insulin secretion.  
However, we questioned whether G6pc2 had any additional functions in different 
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settings.  We hypothesized the G6pc2 activity may be important under conditions in 
which insulin secretion needs to be rapidly shut off, such as during the “fight-or-flight” 
response.  Thus, we performed preliminary exercise studies on the mice at various 
running speeds to determine whether we could detect a defect in the ability of the G6pc2 
KO mice to exercise.  During exercise, various neural inputs are activated which lead to 
the inhibition of insulin secretion possibly through mechanisms involving 
hyperpolarization of the islet β-cell membrane or by inhibition of the exocytotic 
machinery [256, 257].  If these neural inputs were able to regulate the glucokinase/G6pc2 
futile cycle, however, this would present a novel mechanism by which insulin secretion is 
shut off during exercise.  Though no obvious defect was apparent at lower running speeds 
(Fig. 6.1A,B), G6pc2 KO mice become severely hypoglycemic at faster speeds (Fig. 
6.1C,D).  Future studies will follow up on these results with a larger cohort of mice.  In 
addition, the mechanism by which exercise conditions could modulate the G6pc2 protein 
will be investigated.  A first step will be to measure GSIS in islets isolated from both WT 
and KO mice following adrenergic stimulation. 
To further address these preliminary findings, we have developed a novel assay to 
look at putative phosphorylation sites (Fig. 6.2) regulated either through the neural 
circuitry during exercise or by other unknown mechanisms under alternative conditions.  
The assay is based on the observation that in the glucose responsive rat 832/13 
insulinoma cell line, which lacks endogenous G6pc2 [49], expression of a transiently 
transfected rat G6PC-luciferase fusion gene is stimulated in the presence of glucose in 
the media [258].  Addition of a G6pc2 expression vector, however, blunts this response, 
presumably due to its ability to reduce G6P levels, thus inhibiting the signaling pathway  
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Figure 6.1.  Analysis of exercise tolerance in G6pc2 KO mice.  Arterial blood glucose 
(A and C) and plasma insulin (B and D) during exercise in 13 week old male wild type 
(WT, closed diamonds) and knockout (KO, open squares) mice.  Following a 5 hour fast, 
chronically catheterized mice performed 30 min of running at 14 (A and B) or 18 (C and 
D) m/min on a motorized treadmill and arterial blood was sampled at the indicated time 
points.  Data are expressed as means ± S.E.M. 
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Figure 6.2.  A novel transcriptional assay to assess G6PC2 enzyme activity in intact 
insulinoma cells.  In the glucose-responsive 832/13 cell line, the rat G6pc promoter is 
activated by glucose in the media through transcription factors ChREBP and CREB.  In 
the presence of G6pc2, however, G6P levels are reduced and glucose-stimulated G6pc-
luciferase fusion gene expression is blunted. 
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that stimulates G6PC-luciferase expression.  We have begun to mutate serine and 
threonine residues conserved in both G6pc and G6pc3 and located on the cytoplasmic 
domain of the protein to either alanine (preventing phosphorylation) or glutamate and 
aspartate (constitutively active phosphomimetics).  Preliminary analyses indicate that 
mutation of residues 142, 203, 281, and 354 to alanine results in inactivation of the 
G6pc2 protein (Fig. 6.3).  Mutation of residues 142, 203, and 281 to the phosphomimetic 
glutamate, however, also inactivated the protein (Fig. 6.4).  It is possible that glutamate is 
not acting as a true phosphomimetic in this case.  Alternatively, the mutation may be 
altering the structure and thus disrupting the catalytic activity of the protein.  Future 
studies will also look at mutation of this site to the alternative phosphomimetic aspartate.  
Mutation of residue 354 to glutamate did result in a small activation of the protein 
suggesting that this may be a potential site of phosphorylation (Fig. 6.4).  Additional 
putative sites of phosphorylation will also be investigated.  Furthermore, we can 
investigate whether the mutants affect the KM and/or the VMAX of G6P hydrolysis by using 
varying G6P concentrations as previously described [44]. 
 
The effect of a high fat diet on the phenotype of G6pc2 KO mice: preliminary data and 
future directions 
 The G6pc2 protein contains a phosphatidic acid phosphatase domain that is 
conserved among the other two G6PC family members.  It has been previously shown 
that lipid products of phosphatidylinositol 3-kinase activity as well as unsaturated fatty 
acids and fatty acyl-CoA esters can inhibit G6pc activity [259].  Thus, we hypothesized 
that lipid products derived from high fat feeding may similarly inhibit G6pc2 activity and  
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Figure 6.3.  Analysis of the effect of alanine mutation on putative phosphorylation 
sites in G6pc2.  832/13 insulinoma cells were transiently transfected with a G6pc-firefly 
luciferase fusion gene and expression vectors encoding Renilla luciferase and either WT, 
catalytically inactive (MUT) or a mutated form of G6pc2 in which the indicated amino 
acid had been switched to alanine.  Because overexpression of G6pc2 has been shown to 
result in ER stress, the catalytically inactive G6pc2 is used to control for this possibility.  
Following transfection, cells were incubated for 18-20 hours in serum-free medium 
containing 30mM glucose (unless otherwise specified).  Cells were harvested and 
luciferase activity was assessed.  Results are displayed as means ± S.E.M. of a single 
experiment using three independent preparations of each G6pc2 variant. 
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Figure 6.4.  Analysis of the effect of glutamate mutation on putative 
phosphorylation sites in the G6pc2 protein. 832/13 insulinoma cells were transiently 
transfected with a G6pc-firefly luciferase fusion gene and expression vectors encoding 
Renilla luciferase and either WT, catalytically inactive (MUT) or a mutated form of 
G6pc2 in which the indicated amino acid had been switched to glutamate.  Because 
overexpression of G6pc2 has been shown to result in ER stress, the catalytically inactive 
G6pc2 is used to control for this possibility.  Following transfection, cells were incubated 
for 18-20 hours in serum-free medium containing 30mM glucose (unless otherwise 
specified).  Cells were harvested and luciferase activity was assessed.  Results are 
displayed as means ± S.E.M. of a single experiment using three independent preparations 
of each G6pc2 variant. 
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thus blunt/negate the observed differences in fasting blood glucose between WT and KO 
mice. 
Table 6.1 shows that the difference in FBG between male WT and KO mice on a 
mixed, C57BL/6J x 129SvEv, genetic background is surprisingly accentuated by high fat 
feeding.  While this difference in FBG might initially be caused by an unexpected 
activation of G6pc2 or stimulation of G6pc2 expression by lipids, the data show a 
surprising difference in body weight between WT and KO mice.  This weight difference 
is presumably associated with a secondary difference in insulin sensitivity, consistent 
with the difference in fasting plasma insulin levels, that may further accentuate a 
difference in FBG.  The differences in body weight were gender specific; they were not 
seen between high fat fed female WT and KO mice and the difference in FBG was not 
statistically significant. 
 Interestingly, when the study was repeated with mice on a pure, C57BL/6J, 
genetic background, the opposite result was observed.  There was no difference in weight 
between high fat fed male WT and KO mice and the difference in FBG (Table 6.2) was 
similar to that observed in chow fed mice (Table 3.1).  In contrast, a difference in weight 
was observed between high fat fed female WT and KO mice though, as with males, the 
difference in FBG (Table 6.2) was similar to that observed in chow fed mice (Table 3.1). 
 Overall, these observations suggest that high fat feeding does not activate G6pc2 
since a consistent accentuation of the difference in FBG would have been expected 
regardless of gender or genetic background.  Rather the data suggest that G6pc2 can 
influence the magnitude of diet-induced obesity but in a manner that is gender and 
genetic background dependent.  These observations do leave open the possibility that  
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high fat feeding stimulates G6pc2 expression but in a manner that depends on strain-
specific modifier genes or promoter differences.  
 The small difference observed in weight in female chow fed C57BL/6J mice 
(Table 3.1) and larger difference in high fat fed mice (Table 6.2) suggests that in this 
context the effect of G6pc2 on body weight is accentuated by, but is not dependent on, 
the presence of high fat feeding.  Thus, additional studies were performed to gain insight 
into the mechanism whereby female C57BL/6J G6pc2 KO mice are protected from diet-
induced obesity.  
 Growth curves show that a difference in weight is already apparent in female 
mice after 3 weeks of high fat feeding (Fig. 6.5A) whereas no differences are detected in 
males (Fig. 6.5B).  An analysis of body composition using NMR reveals that female 
G6pc2 KO mice have decreased fat mass and increased muscle mass, when expressed as 
a percentage of body weight, relative to WT mice (Table 6.3).  Again no differences were 
detected in males (Table 6.3).  Although female WT mice were 4.64 g heavier than KO 
mice after 12 weeks of high fat feeding (Table 6.2), calculations indicated that this would 
only amount to a 0.08 gram difference in daily food intake, a difference too small to 
measure given the inherent variability in food intake between mice.  An analysis of food 
intake during the initial three weeks of high fat feeding, a time during which body 
weights have not significantly diverged (Fig. 6.5A), confirmed that a difference in food 
intake between female WT and KO mice could not be detected (Fig. 6.6). 
 A key experiment that remains is to perform an analysis of the effect of a high fat 
diet on the phenotype of G6pc2 KO mice on a 129SvEv genetic background.  Key 
differences were observed between the effect of the high fat diet on the mixed C57BL/6J  
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Figure 6.5.  Analysis of the growth curves of high fat fed G6pc2 KO mice on a 
C57BL/6J genetic background.  A high fat diet (60% fat calories; Mouse Diet F3282; 
BioServ) study was initiated at 8 weeks of age and maintained for 12 weeks.  Fed body 
weights were measured weekly in female (Panel A) and male (Panel B) wild type (WT), 
heterozygous (HET) and knockout (KO) animals.  Results show the mean glucose 
concentrations ± S.E.M.  *p<0.05; **p<0.01. 
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Figure 6.6.  Analysis of food intake in female G6pc2 KO mice on a C57BL/6J genetic 
background.  At 8 weeks of age, individually housed females were given a high fat diet 
(60% fat calories; Mouse Diet F3282; BioServ) for three weeks.  Food intake was 
measured daily.  Results are means ± S.E.M. obtained from the number of animals 
indicated.  WT=wild type; KO=knockout. 
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x 129SvEv genetic background (Table 6.1) and the pure C57BL/6J genetic background 
(Table 6.2).  We have attributed these differences to both gender and the effect of 
modifier genes.  An analysis of high fat feeding on the 129SvEv genetic background will 
help to elucidate how genetic background and modifier genes may have been playing a 
role in the differences we observed.  In addition, we have observed a number of SNPs in 
the C57BL/6J and 129SvEv G6pc2 promoter sequences.  These polymorphisms may also 
be contributing to the differences observed between genetic backgrounds. 
 
G6PC2 as a therapeutic drug target 
The studies described here provide evidence that G6PC2 may be an intriguing 
drug target for lowering blood glucose levels in humans.  The safe and effective long-
term pharmacological treatment of type 2 diabetes has remained challenging.  Recently, 
many pharmaceutical companies turned to glucokinase activators as a potential target 
[260].  Long thought to be the primary glucose sensor of the pancreatic β-cell, 
glucokinase performs the first step in glycolysis, the phosphorylation of glucose [232], 
and thus would oppose the action of G6PC2.  Glucokinase is also present in the α- and δ-
cells of the islet and in a number of other organs including the liver, enteroendocrine 
cells, hypothalamus, and gonadotropes and thyrotropes of the pituitary [261-263].  
Inactivating mutations in glucokinase can result in MODY2 [264, 265] or permanent 
neonatal diabetes mellitus (PNDM) [266, 267] while activating mutations can lead to 
persistent hyperinsulinemic hypoglycemia in infancy (PHHI) [268-271].  The activating 
mutations of the latter occur within an allosteric activator site that has since been used as 
the target site of therapeutic glucokinase activators (GKA) [272].  All of the GKAs have 
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been shown to result in a lowered S0.5 of GSIS, though the effect on the catalytic constant 
(KCAT) and on the Hill coefficient (nH) has been varied [260]. 
Significant limitations exist, however, when considering glucokinase as a drug 
target.  Most importantly perhaps is the concern that increased insulin secretion and 
insulin action may result in hypoglycemia.  As discussed above, activating mutations in 
glucokinase can cause PHHI [268-271].  Similarly, though some GKAs, such as 
Piragliatin, have been shown to be effective in lowering blood glucose in both healthy 
control subjects and patients with type 2 diabetes, they pose the risk of mild to moderate 
hypoglycemia [273].  Thus, careful dosing is critical to avoid hypoglycemia.  
Futhermore, glucokinase is widely expressed which allows for a greater possibility for 
negative side effects.  The effect of the GKA on the various tissues where glucokinase is 
expressed must therefore be carefully assessed.  Finally, glucokinase activation may lead 
to fatty-liver syndrome and hyperlipidemia.  Recent GWA studies found polymorphisms 
within the GKRP gene to be associated with variations in serum triglyceride levels [274-
276].  Because GKAs interfere with GKRP inhibition of glucokinase, it is reasonable that 
GKAs may similarly increase hepatic lipid storage and serum triglyceride levels due to 
increased flux through the glycolytic and TCA pathways and insulin stimulated lipid 
synthesis. 
Similar to GKAs, it is reasonable to expect that G6PC2 could be a viable target 
given that it is expected to oppose the action of glucokinase and, as suggested by our 
data, also affect the S0.5 of GSIS.  Interestingly, using high throughput screening of a 
small molecule library, Petrolonis and colleagues were able to identify a specific inhibitor 
of G6PC2 that did not affect G6PC [45].  In addition, it is possible that G6PC2 may 
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actually be a superior target to glucokinase.  Polymorphisms within the gene result in 
mild variations in blood glucose [8, 95, 216, 217] while deletion of G6pc2 in mice results 
in a relatively mild phenotype and, despite the complete loss of the protein, glucose 
levels, though significantly lowered, are still within a normal range.  This suggests that 
inhibition of the gene would not result in the hypoglycemia seen with inhibition of 
glucokinase.  Furthermore, unlike glucokinase, G6PC2 has only been detected in the islet 
[44] and thus targeting G6PC2 may avoid some of the negative side effects that might 
occur with GKAs.  One obvious limitation that deserves further investigation is the 
observation that at high glucose doses, the presence of G6pc2 appeared to be beneficial.  
In addition to this caveat, it is unclear what level of suppression that would be required to 
affect blood glucose levels in vivo.  G6pc2 heterozygous mice display normal glycemia, 
suggesting that G6pc2 may need to be suppressed greater than 50% in order to observe an 
effect.  In humans, however, though G6PC2 levels have not been measured in patients 
with distinct G6PC2 polymorphisms, studies performed in vitro suggested that, for 
example, the rs13431652 G allele which is associated with a 25% reduction in promoter 
activity is associated with a significant reduction in blood glucose [96]. 
In summary, if our hypothesis that G6PC2 is an important inhibitory component 
of the β-cell glucose sensor is correct, then suppression of G6PC2 will represent a novel 
therapy to lower blood glucose. 
 
Further studies to elucidate the role of ZnT-8 
 Surprisingly, our data as well as studies performed by other laboratories have 
indicated that deletion of Slc30a8 results in a relatively mild phenotype despite 
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significant loss of islet zinc and the postulated importance of zinc for proper insulin 
secretion [194, 243, 244, 247].  Though a nonsynonymous polymorphism within the 
SLC30A8 gene was shown to be associated with increased risk of type 2 diabetes [9], 
diabetes is multifactorial and results from a combination of both genetic and 
environmental factors.  Thus, future studies will address whether a more drastic 
phenotype could be unmasked following deletion of Slc30a8 in combination with 
additional stresses such as deletion of another type 2 diabetes susceptibility gene (Table 
1.2) or following high fat feeding.  Interestingly, Nicolson and colleagues did analyze 
Slc30a8 KO mice following 12 weeks of a high fat diet and observed an increase in body 
weight and increases in both fasting blood glucose and plasma insulin though they 
observed no significant impairments in glucose tolerance [194].  This study was limited, 
however, by very low sample sizes (n=2).  It will be important to follow up on these 
studies with much larger cohorts, especially due to the variation in the chow-fed 
phenotypes observed between colonies both within this study [194] and compared to 
other studies [243, 244, 247]. 
In addition to the aforementioned studies, it will be interesting to determine 
whether a low zinc diet will exacerbate the observed phenotype.  Though we were unable 
to detect islet zinc in the Slc30a8 KO mice, the method we used only detects free and 
loosely bound zinc [247].  It is conceivable then that there are low levels of bound zinc 
that are sufficient for proper islet function.  Thus, a zinc deficient diet, which has been 
previously been shown to result in impaired GSIS and exacerbate the db/db phenotype 
[173] may lower islet zinc levels below a critical threshold level.  Furthermore, zinc 
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deficiency has previously been shown to exacerbate the phenotype of other zinc 
transporter knockout mice [277, 278]. 
One final key aspect that remains to be addressed is the transcriptional regulation 
of SLC30A8 and whether SNPs located within regulatory regions of the gene may also 
impact type 2 diabetes susceptibility.  Little is currently known about the regulation of 
SLC30A8 gene expression.  It has been previously demonstrated that treatment of either 
MIN6 cells or primary murine islets with inflammatory cytokines interleukin 1β (IL1β) 
and tumor necrosis factor α (TNFα) results in a reduction in Slc30a8 mRNA expression, 
suggesting that ZnT-8 may contribute to changes in β-cell function under inflammatory 
conditions [279].  In addition, it has also been shown that in INS1E cells, but not in 
murine islets, 16 mM glucose down-regulates Slc30a8 mRNA [280].  Furthermore, zinc 
depletion also caused a reduction in Slc30a8 expression levels [280]. 
Our lab has investigated the transcriptional regulation of both human SLC30A8 
and mouse Slc30a8 gene expression.  We were unable to demonstrate promoter activity 
in transient transfections, however, the use of stable transfections demonstrated that the 
region spanning -6154 to -1 in humans and -1803 to -1 in mice, relative to the translation 
start site, shows promoter activity in βTC3 cells.  Furthermore, in contrast to the studies 
suggesting that zinc regulates the mouse Slc30a8 gene, expression of a human SLC30A8 
promoter-luciferase fusion gene was unaffected by zinc treatment following stable 
transfection in βTC3 cells.  This suggests that zinc regulation of SLC30A8 expression 
may occur through a different region, such as through one of the enhancers we identified 
in the gene (see below) or through a post-transcriptional mechanism [281]. 
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In addition, studies performed in our lab have identified two highly conserved 
enhancer regions, designated A and B, located within introns 2 and 3 of the mouse 
Slc30a8 and human SLC30A8 genes [248].  While enhancer A appears to confer fusion 
gene expression selectively in β-cell lines, enhancer B confers fusion gene expression in 
both α- and β-cell lines [248].  Furthermore, we demonstrated that mutation of either of 
two Pdx1 binding sites within enhancer A significantly reduces enhancer activity and that 
both electrophoretic mobility shift assays (EMSAs) and chromatin immunoprecipitation 
(ChIP) assays confirm Pdx1 binding to the enhancer in vitro and in situ, respectively 
[248].  Similarly, the equivalent enhancer A region within the human SLC30A8 intron 2 
also represents a β-cell specific transcriptional enhancer [281]. 
We have also identified an additional SNP, rs62510556, within a conserved 
enhancer located in SLC30A8 intron 2 [281].  Although we demonstrated that the 
polymorphism modulates enhancer activity, it was not found to be associated with type 2 
diabetes in a French case-control cohort.  Additional studies will be necessary to 
determine whether this SNP is associated with type 2 diabetes in other populations.  A 
lack of association with type 2 diabetes would suggest that either rs62510556 does not 
change SLC30A8 expression sufficiently in vivo to have a biological effect or, more 
interestingly, that the presence of a variant form of ZnT-8, as manifest by the rs13266634 
SNP, increases type 2 diabetes risk in some populations whereas changes in SLC30A8 
expression do not.  If correct, this latter possibility would imply that it is the presence of a 
mutant form of ZnT-8 that causes problems with β-cell function whereas the absence or 
reduction of ZnT-8 is less deleterious.  Finally, the identification of other rare SNPs 
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located within SLC30A8 regulatory regions will help to address whether polymorphisms 
that markedly affect gene expression are sufficient to alter diabetes susceptibility. 
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